


(19) World Intellectual Property  
Organization  
International Bureau



522,356  
26 JAN 2005



(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
**WO 2004/011676 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

(21) International Application Number:  
PCT/GB2003/003192

(22) International Filing Date: 25 July 2003 (25.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0217402.7 26 July 2002 (26.07.2002) GB

(71) Applicants (for all designated States except US): **ROSLIN INSTITUTE (EDINBURGH)** [GB/GB]; Roslin, Midlothian EH25 9PS (GB). **CXR BIOSCIENCES LIMITED** [GB/GB]; Dundee Technopole, James Lindsay Place, Dundee DD1 5JJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WHITELAW, Christopher, Bruce, Alexander** [GB/GB]; Roslin Institute (Edinburgh), Roslin, Midlothian EH25 9PS (GB). **CLARK, Anthony, John** [GB/GB]; Roslin Institute (Edinburgh), Roslin, Midlothian EH25 9PS (GB). **WOLF, Charles, Roland** [GB/GB]; CXR Biosciences Limited, James Lindsay Place, Dundee Technopole, Dundee DD1 5JJ (GB).

(74) Agents: **BASSIL, Nicholas, Charles et al.**; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MULTI-REPORTER GENE MODEL FOR TOXICOLOGICAL SCREENING

(57) Abstract: A system for the detection of gene activation events is provided which comprises a nucleic acid construct encoding a protein of the lipocalin protein family and a peptide tag in which the expression of the construct in a cell or in the cells of a transgenic animal demonstrates the activation of a gene or genes of interest, in which the protein expressed is secreted from the cell and in which detection of the peptide tag indicates expression of the construct.

WO 2004/011676 A2

MULTI-REPORTER GENE MODEL FOR TOXICOLOGICAL SCREENING

The present invention relates to a non-invasive reporter gene system for the detection of gene activation events related to altered metabolic status *in vivo* or *in vitro* for use in toxicological screening.

Genes encode proteins. It is estimated that there at least  $3 \times 10^4$  genes in the vertebrate genome but for a given cell only a subset of the total number of genes is active, with the subset differing between cells of different types and between different stages of development and differentiation (Cho & Campbell *Trends Genet.* **16** 409-415 (2000); Velculescu *et al Trends Genet.* **16** 423-425 (2000)). The DNA regulatory elements associated with each gene governs the decision as to which genes are active and which are not. Although comprising a number of defined elements these DNA sequences are collectively termed promoters (Tjian & Maniatis *Cell* **77** 5-8 (1994); Bonifer, *Trends Genet.* **16** 310-315 (2000); Martin, *Trends Genet* **17** 444-448 (2001)).

Gene activation occurs primarily at the transcriptional level. Transcriptional activity of a gene may be measured by a variety of approaches including RNA polymerase activity, mRNA abundance or protein production (Takano et al., 2002). These approaches are limited in that they require development of an assay suitable to each individual mRNA or protein product. To facilitate comparison of different promoters, rather than assaying individual gene products, reporter genes are often used (Sun *et al Gene Ther.* **8** 1572-1579 (2001); Franco *et al Eur. J. Morphol.* **39** 169-191 (2001); Hadjantonakis & Nagy, *Histochem. Cell. Biol.* **115** 49-58 (2001); Gorman *Mol. Cell. Biol.* **2** 1044-1051 (1982); Barash and Reichenstein, 2002; Zhang et al., 2001.).

The product (mRNA or protein) of a reporter gene allows an assessment of the transcriptional activity of a particular gene and can be used to distinguish cells, tissues or organisms in which the event has occurred from those in which it has not. On the whole reporter genes are foreign to the host cell or organism, allowing their activity to

be easily distinguished from the activity of endogenous genes. Alternatively the reporter may be marked or tagged so as to make it distinct from host genes.

Reporter genes are linked to the test promoter, enabling activity of the promoter gene to be determined by detecting the presence of the reporter gene product. Therefore, the main prerequisite for a reporter gene product is that it is easy to detect and quantify. In some cases, but not all, the reporter gene has enzymatic activity that catalyses the conversion of a substrate into a measurable product.

A classical example is the bacterial chloramphenicol acetyl transferase (CAT) gene. CAT activity can be measured in cell extracts as conversion of added non-acetylated chloramphenicol to the acetylated form of chloramphenicol by chromatography (Gorman *Mol. Cell. Biol.* **2** 1044-1051 (1982)). Similar strategies enable the use of the firefly luciferase gene as a reporter. In this instance it is the light produced by bioluminescence of the luciferin substrate that is measured.

Some reporters also benefit from the visual detection assays that allow *in situ* analysis of reporter activity. A frequently used example would be  $\beta$ -galactosidase (Lac Z), where the addition of an artificial substrate, X-gal, enables reporter activity to be detected by the appearance of blue colouration in the sample. As it is accumulative it effectively provides an historical record of its induction. This is particularly useful for measuring transient responses where a promoter is activated for only a short time before being rapidly inactivated. This reporter has been successfully used both in cultured cells and *in vivo* (Campbell *et al J. Cell. Biol.* **109** 2619-2625 (1996)), though its suitability for *in vivo* use has been questioned in some reports (Sanchez-Ramnos *et al Cell Transplant.* **9** 657-667 (2000); Montoliu *et al Transgenic Res.* **9** 237-239 (2000); Cohen-Tannoudji *et al Transgenic Res.* **9** 233-235 (2000)). It has been demonstrated that Lac Z in combination with fluorescent substrates can enable the sorting of cells that express the reporter by use of a fluorescence-activated cell sorter (FACS) (Fiering *et al Cytometry* **12** 291-301 (1991)).

In other systems, the reporter product itself is directly detected, removing the need for a substrate. Green fluorescent protein has become one of the most commonly used examples of this category of reporter (Ikawa *et al Curr. Top. Dev. Biol.* **44** 1-20 (1997)). This autofluorescing protein was derived from the bioluminescent jellyfish *Aequoria victoria*. Several colour spectral variants of this reporter have been developed (Hadjantonakis & Nagy, *Histochem. Cell. Biol.* **115** 49-58 (2001)).

Recently reporter systems based on energy emission systems have been developed. These include single photon emission computed tomography (SPECT) and positron emission tomography (PET) though these require the introduction of a radiolabelled isotope probe into the host cell or animal that is then modified by the target reporter gene. For example the PET system measures reporter sequestering of the positron emitting probe (Sun *et al Gene Ther.* **8** 1572-1579 (2001)). These are summarised as follows:

Established reporter	
Enzymatic	Light based
alkaline phosphatase	Green fluorescent protein
Beta galactosidase	dsRed
Thymidine kinase	Luciferase
Neomycin resistance	
Chloramphenicol acetyl transferase	
Growth hormone	

Many tried and tested reporter systems have been developed but nevertheless share certain limitations. Those based on prokaryote genes often suffer poor expression in transgenic mammals (Montoliu *et al Transgenic Res.* **9** 237-238 (2000); Cohen-Tannoudji *et al Transgenic Res.* **9** 233-235 (2000)). Furthermore the presence of prokaryote DNA sequences has been implicated in the suppression of expression from adjacent eukaryote transgenes as have the presence of intronless, cDNA based eukaryote gene sequences (Clark *et al.*, 1997).

Most of the current reporters, whilst useful for monitoring expression under certain circumstances, have certain limitations. Many accumulate in cells and are not useful for monitoring changes in promoter activation over time. Perhaps more importantly  
5 detection of expression necessitates the fixing of cultured cells or the sacrifice of transgenic animals, thus limiting reporters to invasive detection strategies. There are a few exceptions and these include the use of growth hormone (Bchini *et al* *Endocrinology* 128 539-546 (1991)). However its high biological activity effectively limit its widespread applicability. Another enzyme that has been used *in vivo* is a  
10 secreted version of alkaline phosphatase (SEAP) (Nilsson *et al* *Cancer Chemother. Pharmacol.* 49 93-100 (2002); Durocher *Nucl. Acids. Res.* 30 E9 (2002)) though again, the potential biological effects resulting from its heterologous expression remain untested. GFP has been detected in whole animals and though possessing relatively low biological activity its use has so far been limited to neonatal and nude  
15 mice in which both internal tissue and dermal fluorescence are more readily observed. In addition there has been a report that GFP is cytotoxic (Liu *et al* *Biochem. Biophys. Res. Comm.* 260 712-717 (1999)). Although reporter systems based on tomography allow monitoring of reporter expression in internal tissues they require addition of exogenously added substrates that could potentially confound results by influencing  
20 expression of the reporter. Additionally they can lack the sensitivity required for quantitative analysis of reporter expression.

There is therefore a need for a reporter system that overcomes some or all of these limitations. Primarily it should be non-invasive inasmuch as its detection does not  
25 involve addition of an external substrate or sacrifice of transgenic animals. This would also ideally stipulate that the reporter be secreted (*in vitro* and *in vivo*) or excreted (*in vivo*). Secondly it should be biologically neutral with regard to the test expression system so that no phenotypic effects either confound readout from the system or affect the health of the transgenic animal. Thirdly a family of reporters sharing similar and  
30 therefore predictable characteristics allowing comparison between reporters is required. This may be achieved if members share a common structure or backbone.

A system satisfying these requirements has now been found. The members of the lipocalin protein family fulfil the necessary characteristics for a non-invasive reporter.

- 5 According to a first aspect of the invention, there is provided a nucleic acid construct comprising (i) a nucleic acid sequence encoding a member of the lipocalin protein family, and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues
- 10 The lipocalins are a diverse family of small molecule transporter proteins that share a common conserved gene structure (Flower *et al Biochim. Biophys Acta* **1482** 9-24 (2000)). Members of this family are small in size with the majority falling into the 18-25kD range. Some are naturally secreted, e.g. ovine betalactoglobulin (BLG) (accession No. X12817), or excreted e.g. murine major urinary protein (MUP) (e.g.
- 15 accession No. NM 031188) and rat  $\alpha$ -2-urinary globulin ( $\alpha$ -2u) (accession number M27434). Lipocalin reporters will preferably be either MUP, BLG or  $\alpha$ -2u but could be chosen from the following list of other lipocalin family members shown in Table 1:

Table 1

Protein	Subunit molecular mass	pI	No. residues	Oligomeric State	Glycosyln.	No. S=S	Abbr. / ref
Kernel lipocalins							
Retinol-binding protein	21.0	5.5	183	Monomer	-	3	RBP (1), (2)
Purpurin	20.0		175				PURP (3)
Retinoic acid-binding protein	18.5	5.2	166	Monomer	-	1	RABP (4)
$\alpha_{2u}$ -Globulin	18.7	5.7-6.7	162	Dimer	-	1	A2U (5)-(7)
Major urinary protein	17.8	5.5-5.7	161	Dimer	-	1	MUP (8)-(10)
Bilin-binding protein	19.6		173	Tetramer	-	2	BBP (11)
$\alpha$ -Crustacyanin	350.0	4.3-4.7	174/181	Octamer of heterodimers	-	2/2	(12) (13)
Pregnancy protein 14	56.0		162	Homodimer	+		PP14 (15)
$\beta$ -Lactoglobulin	18.0	5.2	162	Dimer/monomer	-	2	Blg (16)-(18)

Protein	Subunit molecular mass	pI	No. residues	Oligomeric State	Glycosyln.	No. S=S	Abbr. / ref
$\alpha_1$ -Microglobulin	31.0	4.3–4.8	188	Monomer +complexes	+	1	A1M (19)
C8 $\gamma$	22.0		182	Part of complex	-	1	C8 $\gamma$ (20)
Apolipoprotein D	29.0–32.0	4.7–5.2	169	Dimer +complexes	+	2	ApoD (21)-(23)
Lazarillo	45.0		183	Monomer	+	+	LAZ (24)
Prostaglandin D synthase	27.0	4.6	168	Monomer	+	1	PGDS (25)
Quiescence-specific protein	21.0	6.3	158			1	QSP (26)-(28)
Neutrophil lipocalin	25.0		179	Monomer/Dimer +complexes			NGAL (29)-(32)
Choroid plexus protein	20.0		183	Monomer	-		(33)
<b>Outlier lipocalins</b>							
Odorant-binding protein	37.0–40.0	4.7	159	Dimer		0	OBP (34)-(36)
von Ebner's-gland protein	18.0	4.8–5.2	170	Dimer		1	VEGP (37)-(40)
$\alpha_1$ -Acid glycoprotein	40.0	3.2	183	Monomer	+	2	AGP (41)(42)
Probasin	20.0	11.5	160				PBAS (43)
Aphrodisin	17.0		151		+	2	(44)

"Glycosyln". = glycosylation

"No. S=S" = no. of disulphides

## 5 References:

- (1) Cogan *et al Eur J. Biochem* **65**, 71-78 (1976).
- (2) Hase *et al J. Biochem* **79** 373-380 (1976)
- (3) Berman *et al Cell* **51** 135-142 (1987)
- 10 (4) Newcomer, M. E. & Ong, D. E., *J. Biol. Chem.* **265** 12876-12879 (1990)
- (5) Borghoff *et al Ann. Rev. Pharmacol. Toxicol.* **30** 349-367 (1990)
- (6) Cavaggioni *et al Comp. Biochem. Physiol.* **96B** 513-520 (1990)
- (7) Borghoff *et al Toxicol. Appl. Pharmacol.* **107** 228-238 (1991)
- (8) Shaw *et al Cell* **32** 755-761 (1983)
- 15 (9) Cavaggioni *et al Comp. Biochem. Physiol.* **96B** 513-520 (1990)
- (10) Borghoff *et al Toxicol. Appl. Pharmacol.* **107** 228-238 (1991)

- (11) Riley *et al* *J. Biol. Chem.* **259** 13159-13165 (1984)
- (12) Britton *et al* in "Carotenoid Chemistry and Biochemistry", eds. Britton, G. & Goodwin, T. W., 237-253, Pergamon Press, Oxford (1982)
- (13) Zagalsky *et al* *Comp. Biochem. Physiol.* **97B** 1-18 (1990)
- 5 (14) Morrow *et al* *Am. J. Pathol.* **145** 1485-1495 (1995)
- (15) Hambling *et al* in "Advanced Dairy Chemistry", volume 1, ed. Fox, P. F., 140-190, Elsevier Applied Science London (1992)
- (16) Dodin *et al* *Eur. J. Biochem.* **193** 697-700 (1990)
- (17) Dufour *et al* *FEBS Lett* **277** 223-226 (1991)
- 10 (18) Escribano *et al* *Biochem. Biophys. Res. Comm.* **155** 1424-1429 (1988)
- (19) Haefliger *et al* *Mol. Immunol.* **28** 123-131 (1991)
- (20) Balbin *et al* *Biochem. J.* **271** 803-807 (1990)
- (21) Peitsch, M. C. & Boguski, M. S., *New Biol.* **2** 197-206 (1990)
- (22) Morais Cabral *et al* *FEBS Lett* **366** 53-56 (1995)
- 15 (23) Ganfornia *et al* *Development* **121** 123-134 (1995)
- (24) Urade *et al* *J. Biol. Chem.* **264** 1041-1045 (1988)
- (25) Cancedda *et al* *J. Cell Biol.* **107** 2455-2463 (1990)
- (26) Cancedda *et al* *Biochem. Biophys. Res. Comm.* **168** 933-938 (1990)
- (27) Nakano, T. & Graf, T. *Oncogene* **7** 527-534 (1992)
- 20 (28) Hraba-Renevey *et al* *Oncogene* **4** 601-608 (1989)
- (29) Meheus *et al* *J. Immunol.* **151** 1535-1547 (1993)
- (30) Liu, Q., & Nilsen-Hamilton, M. *J. Biol. Chem.* **270** 22565-22570 (1995)
- (31) Kasik, J. W. & Rice, E. J. *Am. J. Obstet. Gynecol.* **173** 613-617 (1995)
- (32) Achen *et al* *J. Biol. Chem.* **267** 23170-23174 (1992)
- 25 (33) Snyder *et al* *J. Biol. Chem.* **263** 13971-13974 (1988)
- (34) Lee *et al* *Science* **235** 1053-1056 (1987)
- (35) Cavaggioni *et al* *FEBS Lett* **212** 225-228 (1987)
- (36) Kock *et al* *Physiol. Behav.* **56** 1173-1177 (1994)
- (37) Schmale *et al* *Ciba Found. Symp.* **179** 167-185 (1993)
- 30 (38) Redl *et al* *J. Biol. Chem.* **267** 20282-20827 (1992)
- (39) Glasgow *et al* *Curr. Eye Res.* **14** 363-372 (1995)



- (40) Kremer *et al Pharmacol. Rev.* **40** 1-40 (1988)  
(41) Arnaud *et al Methods Enzymol.* **163** 418-431 (1988)  
(42) Matuo *et al Biochem. Biophys. Res. Comm.* **118** 467-473 (1984)  
(43) Henzel *et al J. Biol. Chem.* **263** 16682-16687 (1988)  
5 (44) Magert *et al Proc. Nat'l Acad. Sci. USA* **92** 2091-2095 (1995)

The nucleic acid sequences of the present invention also include sequences that are homologous or complementary to those referred to above. The percent identity of two nucleic acid sequences is determined by aligning the sequences for optimal  
10 comparison purposes (*e.g.*, gaps can be introduced in the first sequence for best alignment with the sequence) and comparing the amino acid residues or nucleotides at corresponding positions. The "best alignment" is an alignment of two sequences which results in the highest percent identity. The percent identity is determined by the number of identical amino acid residues or nucleotides in the sequences being  
15 compared (*i.e.*, % identity = # of identical positions/total # of positions x 100).

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art. An example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and  
20 Altschul *Proc. Natl. Acad. Sci. USA* (1990) 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. The NBLAST and XBLAST programs of Altschul et al, *J. Mol. Biol.* (1990) 215:403-410 have incorporated such an algorithm. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences  
25 homologous to a nucleic acid molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilised as described in Altschul et al, *Nucleic Acids Res.* (1997) 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (*Id.*). When utilising BLAST, Gapped BLAST, and PSI-Blast programs, the default  
30 parameters of the respective programs (*e.g.*, NBLAST) can be used. See [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov).

Another example of a mathematical algorithm utilised for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). The ALIGN program (version 2.0) which is part of the GCG sequence alignment software package has incorporated such an algorithm. Other algorithms for sequence analysis known in the art include ADVANCE and ADAM as described in Torellis and Robotti *Comput. Appl. Biosci.* (1994) 10:3-5; and FASTA described in Pearson and Lipman *Proc. Natl. Acad. Sci. USA* (1988) 85:2444-8. Within FASTA, ktup is a control option that sets the sensitivity and speed of the search.

A nucleic acid sequence which is complementary to a nucleic acid sequence of the present invention is a sequence which hybridises to such a sequence under stringent conditions, or a nucleic acid sequence which is homologous to or would hybridise under stringent conditions to such a sequence but for the degeneracy of the genetic code, or an oligonucleotide sequence specific for any such sequence. The nucleic acid sequences include oligonucleotides composed of nucleotides and also those composed of peptide nucleic acids. Where the nucleic sequence is based on a fragment of the sequences of the invention, the fragment may be at least any ten consecutive nucleotides from the gene, or for example an oligonucleotide composed of from 20, 30, 40, or 50 nucleotides.

Stringent conditions of hybridisation may be characterised by low salt concentrations or high temperature conditions. For example, highly stringent conditions can be defined as being hybridisation to DNA bound to a solid support in 0.5M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1mM EDTA at 65°C, and washing in 0.1xSSC/0.1%SDS at 68°C (Ausubel *et al* eds. "Current Protocols in Molecular Biology" 1, page 2.10.3, published by Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York, (1989)). In some circumstances less stringent conditions may be required. As used in the present application, moderately stringent conditions can be defined as comprising washing in 0.2xSSC/0.1%SDS at 42°C (Ausubel *et al* (1989) *supra*). Hybridisation can also be made more stringent by the addition of increasing

amounts of formamide to destabilise the hybrid nucleic acid duplex. Thus particular hybridisation conditions can readily be manipulated, and will generally be selected according to the desired results. In general, convenient hybridisation temperatures in the presence of 50% formamide are 42°C for a probe which is 95 to 100% homologous to the target DNA, 37°C for 90 to 95% homology, and 32°C for 70 to 90% homology.

Examples of preferred nucleic acid sequences for use in according to the various aspects of the present invention are the sequences of the invention are disclosed herein. Complementary or homologous sequences may be 75%, 80%, 85%, 90%, 95%, 99% similar to such sequences.

With the addition of peptide tags to a chosen lipocalin reporter there is provided a useful sub-family of reporter proteins. Essentially it allows generation of a large number of reporters from a single lipocalin where that lipocalin acts as the carrier for a range of peptides that can be clearly differentiated from one another by a range or biological or physical assay techniques. For example it has been demonstrated that a casein kinase recognition sequence engineered in exon 3 of the ovine betalactoglobulin (BLG) gene resulted in expression of a novel form of BLG containing an active kinase substrate in one of the surface loops of the protein in transgenic mice (McClenaghan *et al Protein Eng.* 12 259-264 (1999)).

The position of the peptide tag may be at the amino terminal or carboxy terminal or inserted internally with respect to the amino acid sequence of the reporter. All three examples are represented in Figure 1.

The peptide tag can be a sequence consisting of between 5 to 250 amino acids. Suitably, in the ranges of from, 5 to 50, 10 to 60, 20 to 70, 30 to 80, 40 to 90, and so on. In some embodiments of the invention peptides may be required to consist of a greater number of amino acids than 250 residues.

In a preferred embodiment of the invention the peptide tag may be an epitope, that is a defined amino acid sequence from a protein with a fully characterised cognate antibody. The skilled person can select such epitopes based on sequences identified as possessing antigenic properties. In certain embodiments of the invention the epitope tag may be the amino acid sequence below from the c-myc oncogene (Evans *et al Mol. Cell. Biol.* 5 3610-3616 (1985)):

-Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-

(EQKLISEEDL)

or it may be the amino acid sequence from the simian virus V5 protein (Southern *et al J. Gen. Virol.* 72 1551-1557 (1991)), shown below:

-Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr-

(GKPIPNPLLGLDST)

In certain embodiments of the invention, the epitope may be selected from but not limited to the c-myc and V5 proteins.

Other alternative epitopes may include, but are not limited to:

Haemagglutinin	(YPYDVPDYA)
Clone100	(NVRFSTIVRRRA)
rab11a	(KQMSDRRENDMSPS)
DOB	(SGNEVSRAVLLPQSC)
SG11	(SSLSYTNPAVAATSANL)
erbB4	(RSTLQHPDYLQEYST)
ARF	(VSTLLRWERFPGHRQA)
RYK	(KFQQLVQCLTEFHAALGAYV)

WILPEP1 (QEQCQEVWRKRVISAFKSP)  
HAF10 (RLSDKTGPVAQEKS)

5 Preferably the epitope tag is recognised by its cognate antibody irrespective of whether it is located at the amino terminal, carboxy terminal or in an internal domain of the reporter protein.

10 In another embodiment of the invention the peptide tag may possess enzymatic activity that converts a substrate to a form that is readily detectable by an assay. For example a kinase activity specifying phosphorylation of another protein or peptide substrate that could be added to the secreted or excreted analyte along with a phosphate group donor. Detection could be achieved using an immunological assay based on detection by an antibody specifically recognising the phosphorylated version of the tagged reporter protein. Alternatively the use of phosphate radiolabelled with an  
15 isotope of phosphorous such as  $^{32}\text{P}$  or  $^{33}\text{P}$ . Other enzymic modifications include for example acetylation, sulphation and glycosylation. Another possibility is peptide tag that is an enzyme, that is the construct comprises a nucleic acid sequence encoding an enzyme, or a nucleic acid sequence encoding a catalytic sequence thereof, such as Glutathione-S-transferase (GST) where enzyme activity can be detected by means of  
20 an activity assay or by antibody reactivity.

Suitably, the nucleic acid sequence encoding the member of the lipocalin protein family is contiguous with the nucleic acid sequence encoding the peptide sequence. However, a linker nucleic acid sequence may be inserted between these two sequences  
25 that encodes a short number of amino acids.

The nucleic acid construct may additionally comprise a promoter element upstream of the nucleic acid encoding the member of the lipocalin protein family. The promoter element may be an inducible promoter, preferably a stress inducible promoter.

30

It is also within the scope of the present invention for the nucleic acid construct to include more than one detectable peptide label. Such as for example, a peptide antigen and an enzyme (or an active catalytic site thereof). One possible combination is the peptide epitope c-myc and the enzyme GST.

5

Other embodiments of this aspect could include, for example site of interaction with protein other than antibody e.g. lectin binding site, or modification of tag by e.g. addition of amino acid multimer such as polylysine; or incorporation of a fluorochrome.

10

The peptide sequence may be as described above but it also extends to peptides and polypeptides that are substantially homologous thereto. The term "polypeptide" includes both peptide and protein, unless the context specifies otherwise.

15

Such peptides include analogues, homologues, orthologues, isoforms, derivatives, fusion proteins and proteins with a similar structure or are a related polypeptide as herein defined.

20

The term "analogue" as used herein refers to a peptide that possesses a similar or identical function as a peptide coded for by a nucleic acid sequence of the invention but need not necessarily comprise an amino acid sequence that is similar or identical to an amino acid sequence of the invention, or possess a structure that is similar or identical to that of a peptide of the invention. As used herein, an amino acid sequence of a peptide is "similar" to that of a peptide of the invention if it satisfies at least one of the following criteria: (a) the peptide has an amino acid sequence that is at least 30% (more preferably, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99%) identical to the amino acid sequence of a peptide of the present invention; (b) the peptide is encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding at least 5 amino acid residues (more preferably, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at

30

least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, or at least 150 amino acid residues) of a peptide sequence of the invention; or (c) the peptide is encoded by a nucleotide sequence that is at least 30% (more preferably, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99%) identical to the nucleotide sequence encoding a peptide of the invention.

10

As used herein, a peptide with "similar structure" to that of a peptide of the invention refers to a peptide that has a similar secondary, tertiary or quaternary structure as that of a peptide of the invention. The structure of a peptide can determined by methods known to those skilled in the art, including but not limited to, X-ray crystallography, nuclear magnetic resonance, and crystallographic electron microscopy.

15

The term "fusion protein" as used herein refers to a peptide that comprises (i) an amino acid sequence of a peptide of the invention, a fragment thereof, a related peptide or a fragment thereof and (ii) an amino acid sequence of a heterologous peptide (*i.e.*, not a peptide sequence of the present invention).

20

The term "homologue" as used herein refers to a peptide that comprises an amino acid sequence similar to that of a protein of the invention but does not necessarily possess a similar or identical function.

25

The term "orthologue" as used herein refers to a peptide that (i) comprises an amino acid sequence similar to that of a protein of the invention and (ii) possesses a similar or identical function.

30

The term "related peptide" as used herein refers to a homologue, an analogue, an isoform of , an orthologue, or any combination thereof of a peptide of the invention.

The term "derivative" as used herein refers to a peptide that comprises an amino acid sequence of a peptide of the invention which has been altered by the introduction of amino acid residue substitutions, deletions or additions. The derivative peptide  
5 possess a similar or identical function as peptides of the invention.

The term "fragment" as used herein refers to a peptide comprising an amino acid sequence of at least 5 amino acid residues (preferably, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid  
10 residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues) of the amino acid sequence of a peptide of the invention.

The term "isoform" as used herein refers to variants of a peptide that are encoded by the same gene, but that differ in their isoelectric point (pI) or molecular weight (MW), or both. Such isoforms can differ in their amino acid composition (*e.g.* as a result of alternative splicing or limited proteolysis) and in addition, or in the alternative, may arise from differential post-translational modification (*e.g.*, glycosylation, acylation,  
20 phosphorylation). As used herein, the term "isoform" also refers to a protein that peptide exists in only a single form, *i.e.*, it is not expressed as several variants.

The percent identity of two amino acid sequences or of two nucleic acid sequences is determined by aligning the sequences for optimal comparison purposes (*e.g.*, gaps can  
25 be introduced in the first sequence for best alignment with the sequence) and comparing the amino acid residues or nucleotides at corresponding positions. The "best alignment" is an alignment of two sequences which results in the highest percent identity. The percent identity is determined by the number of identical amino acid residues or nucleotides in the sequences being compared (*i.e.*, % identity = # of  
30 identical positions/total # of positions x 100).



The determination of percent identity between two sequences can be accomplished using a mathematical algorithm known to those of skill in the art. An example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul *Proc. Natl. Acad. Sci. USA* (1990) 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. The NBLAST and XBLAST programs of Altschul et al, *J. Mol. Biol.* (1990) 215:403-410 have incorporated such an algorithm. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilised as described in Altschul et al, *Nucleic Acids Res.* (1997) 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilising BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

Another example of a mathematical algorithm utilised for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). The ALIGN program (version 2.0) which is part of the GCG sequence alignment software package has incorporated such an algorithm. Other algorithms for sequence analysis known in the art include ADVANCE and ADAM as described in Torellis and Robotti *Comput. Appl. Biosci.* (1994) 10:3-5; and FASTA described in Pearson and Lipman *Proc. Natl. Acad. Sci. USA* (1988) 85:2444-8. Within FASTA, ktup is a control option that sets the sensitivity and speed of the search.

The skilled person is aware that various amino acids have similar properties. One or more such amino acids of a substance can often be substituted by one or more other such amino acids without eliminating a desired activity of that substance. Thus the amino acids glycine, alanine, valine, leucine and isoleucine can often be substituted for one

another (amino acids having aliphatic side chains). Of these possible substitutions it is preferred that glycine and alanine are used to substitute for one another (since they have relatively short side chains) and that valine, leucine and isoleucine are used to substitute for one another (since they have larger aliphatic side chains which are hydrophobic).

5 Other amino acids which can often be substituted for one another include: phenylalanine, tyrosine and tryptophan (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino acids having acidic side chains); asparagine and glutamine (amino acids having amide side chains); and cysteine and methionine (amino acids having sulphur containing side chains).

10 Substitutions of this nature are often referred to as "conservative" or "semi-conservative" amino acid substitutions.

Amino acid deletions or insertions may also be made relative to the amino acid sequence of a peptide sequence of the invention. Thus, for example, amino acids which do not

15 have a substantial effect on the biological activity or immunogenicity of such peptides, or at least which do not eliminate such activity, may be deleted. Amino acid insertions relative to the sequence of peptides of the invention can also be made. This may be done to alter the properties of a peptide of the present invention (e.g. to assist in identification, purification or expression. Such amino acid changes relative to the sequence of a

20 polypeptide of the invention from a recombinant source can be made using any suitable technique e.g. by using site-directed mutagenesis.

According to the various embodiments of this aspect of the invention, the promoter will preferably be of mammalian origin, but also may be from a non-mammalian

25 animal, plant, yeast or bacteria. The promoter may be selected from but is not limited to promoter elements of the following inducible genes:

whose expression is modified in response to disturbances in the homeostatic state of DNA in the cell. These disturbances may include chemical alteration of

30 nucleic acids or precursor nucleotides, inhibition of DNA synthesis and inhibition of DNA replication. The sequence can be selected from but not

limited to the group consisting of c-myc (Hoffman *et al Oncogene* **21** 3414-3421), p21/WAF-1 (El-Diery *Curr. Top. Microbiol. Immunol.* **227** 121-137 (1998); El-Diery *Cell Death Differ.* **8** 1066-1075 (2001); Dotto *Biochim. Biophys. Acta* **1471** 43-56 (2000)), MDM2 (Alarcon-Vargas & Ronai *Carcinogenesis* **23** 541-547 (2002); Deb & Front *Bioscience* **7** 235-243 (2002)), Gadd45 (Sheikh *et al Biochem. Pharmacol.* **59** 43-45 (2000)), FasL (Wajant *Science* **296** 1635-1636 (2002)), GAHSP40 (Hamajima *et al J. Cell. Biol.* **84** 401-407 (2002)), TRAIL-R2/DR5 (Wu *et al Adv.Exp. Med. Biol.* **465** 143-151 (2000); El-Diery *Cell Death Differ.* **8** 1066-1075 (2001)), BTG2/PC3 (Tirone *et al J. Cell. Physiol.* **187** 155-165 (2001));

whose transcription is modified in response to oxidative stress. The sequence can be selected from but not limited to the group consisting of MnSOD and/or CuZnSOD (Halliwell *Free Radic. Res.* **31** 261-272 (1999); Gutteridge & Halliwell *Ann. NY Acad. Sci.* **899** 136-147 (2000)), I $\kappa$ B (Ghosh & Karin *Cell* **109** Suppl., S81-96 (2002)), ATF4 (Hai & Hartman *Gene* **273** 1-11 (2001)), xanthine oxidase (Pristos *Chem. Biol. Interact.* **129** 195-208 (2000)), COX2 (Hinz & Brune *J. Pharmacol. Exp. Ther.* **300** 376-375 (2002) ), iNOS (Alderton *et al Biochem. J.* **357** 593-615 (2001)), Ets-2 (Bartel *et al Oncogene* **19** 6443-6454 (2000)), FasL/CD95L (Wajant *Science* **296** 1635-1636 (2002)),  $\gamma$ GCS (Lu *Curr. Top. Cell. Regul.* **36** 95-116 (2000); Soltaninassab *et al J. Cell. Physiol.* **182** 163-170 (2000)), ORP150 (Ozawa *et al Cancer Res.* **61** 4206-4213 (2001); Ozawa *et al J. Biol. Chem.* **274** 6397-6404 (1999)).

whose expression is modified in response to hepatotoxic stress. The sequence can be selected from but not limited to the group consisting of Lrg-21 (Drysdale *et al Mol. Immunol.* **33** 989-998 (1996)), SOCS-2 and/or SOCS-3 (Tollet-Egnell *et al Endocrinol.* **140** 3693-3704 (1999), PAI-1 (Fink *et al Cell. Physiol. Biochem.* **11** 105-114 (2001)), GBP28/adiponectin (Yoda-Murakami *et al Biochem. Biophys. Res. Commun.* **285** 372-377 (2001)),  $\alpha$ -1 acid glycoprotein (Komori *et al Biochem Pharmacol.* **62** 1391-1397 (2001)),

metallothioneine I (Palmiter *et al Mol. Cell. Biol.* **13** 5266-5275 (1993)),  
metallothioneine II (Schlager & Hart *App. Toxicol.* **20** 395-405 (2000)), ATF3  
(Hai & Hartman *Gene* **273** 1-11 (2001)), IGFbp-3 (Popovici *et al J. Clin.*  
*Endocrinol. Metab.* **86** 2653-2639 (2001)), VEGF (Ido *et al Cancer Res.* **61**  
5 3016-3021 (2001)) and HIF1 $\alpha$  (Tacchini *et al Biochem. Pharmacol.* **63** 139-  
148 (2002)).

whose expression is modified in response to a pro-apoptotic stimulus. The  
sequence can be selected from but not limited to the group consisting of Gadd  
10 34 (Hollander *et al J. Biol. Chem.* **272** 13731-13737 (1997)), GAHSP40  
(Hamajima *et al J. Cell. Biol.* **84** 401-407 (2002)), TRAIL-R2/DR5 (Wu *et al*  
*Adv. Exp. Med. Biol.* **465** 143-151 (2000); El-Diery *Cell Death Differ.* **8** 1066-  
1075 (2001)), c-fos (Teng *Int. Rev. Cytol.* **197** 137-202 (2000)),  
CHOP/Gadd153 (Talukder *et al Oncogene* **21** 4280-4300 (2002)), APAF-1  
15 (Cecconi & Gruss *Cell. Mol. Life Sci.* **5** 1688-1698 (2001)), Gadd45 (Sheikh *et*  
*al Biochem. Pharmacol.* **59** 43-45 (2000)), BTG2/PC3 (Tirone *J. Cell. Physiol.*  
**187** 155-165 (2001)), Peg3/Pwl (Relaix *et al Proc. Nat'l Acad. Sci. USA* **97**  
2105-2110 (2000)), Siah 1a (Maeda *et al FEBS Lett.* **512** 223-226 (2002)), S29  
ribosomal protein (Khanna *et al Biochem. Biophys. Res. Commun.* **277** 476-  
20 486 (2000)), FasL/CD95L (Wajant *Science* **296** 1635-1636 (2002)), tissue  
transglutaminase (Chen & Mehta *Int. J. Cell. Biol.* **31** 817-836 (1999)), GRP78  
(Rao *et al FEBS Lett.* **514** 122-128 (2002)), Nur77/NGFI-B (Winoto *Int. Arch.*  
*Allergy Immunol.* **105** 344-346 (1994)), CyclophilinD (Andreeva *et al Int. J.*  
*Exp. Pathol.* **80** 305-315 (1999)), p73 (Yang *et al Trends Genet.* **18** 90-95  
25 (2002)) and Bak (Lutz *Biochem. Soc. Trans.* **28** 51-56 (2000)).

whose expression is modified in response to the administration of chemicals or  
drugs. The sequence can be selected from but not limited to the list comprised  
of xenobiotic metabolising cytochrome p450 enzymes from the 2A, 2B, 2C,  
30 2D, 2E, 2S, 3A, 4A and 4B gene families (Smith *et al Xenobiotica* **28** 1129-  
1165 (1998); Honkaski & Negishi *J. Biochem. Mol. Toxicol.* **12** 3-9 (1998);

Raucy *et al J. Pharmacol. Exp. Ther.* **302** 475-482 (2002); Quattrochi & Guzelian *Drug Metab. Dispos.* **29** 615-622 (2001)).

5 The promoter element may also be a synthetic promoter sequence comprised of a minimal eukaryote consensus promoter operatively linked to one or more sequence elements known to confer transcriptional inducibility in response to specific stimulus. A minimal eukaryotic consensus promoter is one that will direct transcription by eukaryotic polymerases only if associated with functional promoter elements or transcription factor binding sites. An example of which is the PhCMV\*-1 (Furth *et al*  
10 *Proc. Nat'l Acad. Sci. USA* **91** 9302-9306 (1994)). Sequence elements known to confer transcriptional induction in response to specific stimulus include promoter elements (Montoliu *et al Proc. Nat'l Acad. Sci. USA* **92** 4244-4248 (1995)) or transcription factor binding sites; these will be chosen from but are not limited to the list comprising the aryl hydrocarbon (Ah)/Ah nuclear translocator (ARNT) receptor  
15 response element, the antioxidant response element (ARE), the xenobiotic response element (XRE).

A nucleic acid construct according to the invention may suitably be inserted into a vector which is an expression vector that contains nucleic acid sequences as defined  
20 above. The term "vector" or "expression vector" generally refers to any nucleic acid vector which may be RNA, DNA or cDNA.

The term "expression vector" may include, among others, chromosomal, episomal, and virus-derived vectors, for example, vectors derived from bacterial plasmids, from  
25 bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.  
30 Generally, any vector suitable to maintain, propagate or express nucleic acid to express a polypeptide in a host may be used for expression in this regard.

Recombinant expression vectors will include, for example, origins of replication, a promoter preferably derived from a highly expressed gene to direct transcription of a structural sequence as defined above, and a selectable marker to permit isolation of vector containing cells after exposure to the vector.

Expression vectors may comprise an origin of replication, a suitable promoter as defined above and/or enhancer, and also any necessary ribosome binding sites, polyadenylation regions, splice donor and acceptor sites, transcriptional termination sequences, and 5'- flanking non-transcribed sequences that are necessary for expression. Preferred expression vectors according to the present invention may be devoid of enhancer elements.

The expression vectors may also include selectable markers, such as antibiotic resistance, which enable the vectors to be propagated.

According to a second aspect of the invention there is provided a nucleic acid construct comprising a stress inducible promoter operatively isolated from a nucleic acid sequence encoding a member of the lipocalin protein family by a nucleotide sequence flanked by nucleic acid sequences recognised by a site specific recombinase, or by insertion such that it is inverted with respect to the transcription unit encoding a member of the lipocalin protein family. The recombinase recognition sites are arranged in such a way that the isolator sequence is deleted or the inverted promoter's orientation is reversed in the presence of the recombinase. The construct also comprises a nucleic acid sequence comprising a tissue specific promoter operatively linked to a gene encoding the coding sequence for the site specific recombinase.

Stress inducible promoters may be as described in relation to the first aspect of the invention.

This aspect allows for detecting reporter transgene induction in specified tissues only. By controlling the appropriate recombinase expression using a tissue specific promoter, the inducible transgene will only be viable in those tissues in which the promoter is active. For example, by driving recombinase activity from a liver specific promoter, only the liver will contain re-arranged reporter construct, and hence will the only tissue in which reporter induction can occur.

Tissue specific promoters are a class of gene promoters whose function is restricted solely (or more usually, mainly) to a particular cell type or tissue.

Examples include promoters from the liver, pancreas, mammary gland, squamous epithelium, small intestine, skeletal muscle, smooth muscle, striated muscle, heart, prostate, adipose tissue, neural crest, brain, kidney and lung. Particular instances of tissue specific promoters are as follows (although, the invention is not limited as such):

Tissue	Example of tissue specific promoter
Liver	Albumin (Pinkert <i>et al Genes Dev</i> 1987 1: 268-276)
Liver	$\alpha$ -fetoprotein (Wen <i>et al DNA Cell Biol</i> 1991 7: 525-536)
Liver	$\alpha$ 1-antitrypsin (Shen <i>et al DNA</i> 1989 8 (2):101-8)
Pancreas	Insulin II ((a) Gannon <i>et al Genesis</i> 2000 26(2):139-42); (b) Ray <i>et al Int J Pancreatol</i> 1999 25 (3):157-63)
Pancreas	Pdx-1 (Gerrish <i>et al J Biol Chem</i> 2000 275 (5):3485-92)
Mammary gland	$\beta$ -Lactoglobulin ((a) Selbert <i>et al Transgenic Res</i> 1998 7 (5):387-96); (b) Webster <i>et al Cell Mol Biol Res</i> 1995 41 (1):11-5)
Mammary gland	Whey acid protein (Wagner <i>et al Nucleic Acids Res</i> 1997 25 (21):4323-30)

Tissue	Example of tissue specific promoter
Squamous epithelium	Keratin 5 (Brown <i>et al Curr Biol</i> 1998 <b>8</b> (9):516-24)
Squamous epithelium	Keratin 14 (Vassar <i>et al Proc Natl Acad Sci U S A.</i> 1989 <b>86</b> (5):1563-7)
Squamous epithelium	Loricrin (DiSepio <i>et al Differentiation.</i> 1999 <b>64</b> (4):225-35)
Small intestine	Fatty acid binding protein (Sweetser <i>et al Proc Natl Acad Sci U S A.</i> 1988 <b>85</b> (24):9611-5)
Small intestine	sucrase-isomaltase (Markowitz <i>et al Am J Physiol</i> 1995 <b>269</b> (6 Pt 1):G925-39)
Skeletal muscle	Myosin light chain 1f (Bothe <i>et al Genesis</i> 2000 <b>26</b> (2):165-6)
Smooth muscle	SmmMHC (Xin <i>et al Physiol Genomics</i> 2002 <b>10</b> (3):211-5)
Striated muscle	$\alpha$ -skeletal actin (Miniou <i>et al Nucleic Acids Res</i> 1999 <b>27</b> (19):e27)
Heart	$\alpha$ -myosin heavy chain (Heger <i>Circ Res.</i> 2002 <b>90</b> (1):93-9)
Prostate	Probasin (Greenberg <i>et al Mol Endocrinol</i> 1994 <b>8</b> :230-239)
Adipose tissue	aP2 (Gnudi <i>et al Am J Physiol</i> 1996 <b>270</b> (4 Pt 2):R785-92)
Neural crest	Pax3 (Goulding <i>et al EMBO J</i> 1991 <b>10</b> (5):1135-47)
Neural crest	Protein 0 (Yamauchi <i>et al Dev Biol</i> 1999 <b>212</b> (1):191-203)
Brain	CaMKII (Tomiooka <i>et al Brain Res Mol Brain Res</i> 2002 <b>108</b> (1-2):18-32)
Lung	surfactant protein C (Korfhagen <i>et al J Clin Invest</i> 1994 <b>93</b> (4):1691-9)



The recombination event producing an active reporter transcription unit may therefore only take place in tissues where the recombinase is expressed. In this way the reporter may only be expressed in specified tissue types where expression of the recombinase results in a functional transcription unit comprised of the inducible promoter linked to the promoter. Site specific recombinase systems known to perform such a function include the bacteriophage P1 cre-lox and the bacterial FLIP systems. The site specific recombinase sequences may therefore be two loxP sites of bacteriophage P1

The use of site specific recombination systems to generate precisely defined deletions in cultured mammalian cells has been demonstrated. Gu *et al.* (*Cell* **73** 1155-1164 (1993)) describe how a deletion in the immunoglobulin switch region in mouse ES cells was generated between two copies of the bacteriophage P1 loxP site by transient expression of the Cre site-specific recombinase, leaving a single loxP site. Similarly, yeast FLP recombinase has been used to precisely delete a selectable marker defined by recombinase target sites in mouse erythroleukemia cells (Fiering *et al.*, *Proc. Nat'l. Acad. Sci. USA* **90** 8469-8473 (1993)). The Cre lox system is exemplified below, but other site-specific recombinase systems could be used.

A construct used in the Cre lox system will usually have the following three functional elements:

1. The expression cassette;
2. A negative selectable marker (e.g. Herpes simplex virus thymidine kinase (TK) gene) expressed under the control of a ubiquitously expressed promoter (e.g. phosphoglycerate kinase (Soriano *et al.*, *Cell* **64** 693-702 (1991))); and
3. Two copies of the bacteriophage P1 site specific recombination site loxP (Baubonis *et al.*, *Nuc. Acids. Res.* **21** 2025-2029 (1993)) located at either end of the DNA fragment.

This construct can be eliminated from host cells or cell lines containing it by means of site specific recombination between the two *loxP* sites mediated by Cre recombinase protein which can be introduced into the cells by lipofection (Baubonis *et al.*, *Nuc. Acids Res.* 21 2025-2029 (1993)). Cells which have deleted DNA between the two *loxP* sites are selected for loss of the TK gene (or other negative selectable marker) by growth in medium containing the appropriate drug (ganciclovir in the case of TK).

According to the third aspect of the invention there is provided a host cell transfected with a nucleic acid construct according to any one of the previous aspects of the invention. The cell type is preferably of human or non-human mammalian origin but may also be of other animal, plant, yeast or bacterial origin. For example, HEPA1-6, mouse hepatoma epithelial cells; HEK293, human embryonic kidney epithelial cells; COS-1, African green monkey fibroblasts; CHO, Chinese hamster ovary epithelial cells; HT 29, human colon adenocarcinoma epithelial cells; MCF7, human breast adenocarcinoma epithelial-like cells; HeLa, human cervical carcinoma epithelial cells, HEP G2, human hepatocyte carcinoma epithelial cells; PC3, human prostate adenocarcinoma epithelial cells; A2780, human ovarian carcinoma epithelial cells.

Introduction of an expression vector into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction, infection of other methods. Such methods are described in many standard laboratory manuals, such as Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

According to the fourth aspect of the invention, there is provided a transgenic non-human animal in which the cells of the non-human animal express the protein encoded by the nucleic acid construct according to any one of the previous aspects of the invention. Suitably, the non-human animal is a non-human mammal. The transgenic animal is preferably a mouse but may be another mammalian species, for example another rodent, e.g. a rat or a guinea pig, or another species such as rabbit, or a canine

or feline, or an ungulate species such as ovine, porcine, equine, caprine, bovine, or a non-mammalian animal species, e.g. an avian (such as poultry, e.g. chicken or turkey).

5 In embodiments of the invention relating to the preparation of a transfected host cell or a transgenic non-human animal comprising the use of a nucleic acid construct as previously described, the cell or non-human animal may be subjected to further transgenesis, in which the transgenesis is the introduction of an additional gene or genes or protein-encoding nucleic acid sequence or sequences. The transgenesis may be transient or stable transfection of a cell or a cell line, an episomal expression system  
10 in a cell or a cell line, or preparation of a transgenic non-human animal by pronuclear microinjection, through recombination events in embryonic stem (ES) cells or by transfection of a cell whose nucleus is to be used as a donor nucleus in a nuclear transfer cloning procedure.

15 Methods of preparing a transgenic cell or cell line, or a transgenic non human animal, in which the method comprises transient or stable transfection of a cell or a cell line, expression of an episomal expression system in a cell or cell line, or pronuclear microinjection, recombination events in ES cells, or other cell line or by transfection of a cell line which may be differentiated down different developmental pathways and  
20 whose nucleus is to be used as the donor for nuclear transfer; wherein expression of an additional nucleic acid sequence or construct is used to screen for transfection or transgenesis in accordance with the first, second, third, or fourth aspects of the invention. Examples include use of selectable markers conferring resistance to antibiotics added to the growth medium of cells, e.g. neomycin resistance marker  
25 conferring resistance to G418. Further examples involve detection using nucleic acid sequences that are of complementary sequence and which will hybridise with, or a component of, the nucleic acid sequence in accordance with the first, second, third, or fourth aspects of the invention. Examples would include Southern blot analysis, northern blot analysis and PCR.

30

According to the fifth aspect of the invention, there is provided the use of a nucleic acid construct in accordance with any one of the first, second, third, or fourth aspects of the invention for the detection of a gene activation event resulting from a change in altered metabolic status in a cell *in vitro* or *in vivo*.

5

The gene activation event may be the result of induction of toxicological stress, metabolic changes, or disease that may be, but is not limited to, the result of viral, bacterial, fungal or parasitic infection.

10

According to the sixth aspect of the invention there is provided the use of a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, for the detection of a gene activation event resulting from a change in altered metabolic status in a cell *in vitro* or *in vivo*.

15

The gene activation event may be the result of induction of toxicological stress, metabolic changes, disease that may be, but is not limited to, the result of viral, bacterial, fungal or parasitic infection.

20

Uses in accordance with the fifth and sixth aspects of the invention also extend to the detection of disease states or characterisation of disease models in a cell, cell line or non human transgenic animal where a change in the gene expression profile within a target cell or tissue type is altered as a consequence of the disease. Diseases in the context of this aspect of the invention which are detectable under the methods disclosed may be defined as infectious disease, cancer, inflammatory disease, cardiovascular disease, metabolic disease, neurological disease and disease with a genetic basis.

25

30

An additional use in accordance with this aspect of the invention involves the growth of a transfected cell line in accordance with the third aspect in a suitable immunocompromised mouse strain (referred to as a xenograft), for example, the nude

mouse, wherein an alteration in the expression of the reporter described in the first or second aspects of the invention may be used as a measure of altered metabolic status of the host as a result of toxicological stress, metabolic changes, disease with a genetic basis or disease that may be, but is not limited to, the result of viral, bacterial, fungal or parasitic infection. The scope of this use may also be of use in monitoring the effects of exogenous chemicals or drugs on the expression of the reporter construct.

The fifth and sixth aspects of the invention extend to methods of detecting a gene activation event *in vitro* or *in vivo*.

10

In an embodiment according to the fifth aspect of the invention, the method comprises assaying a host cell stably transfected with a nucleic acid construct in accordance with any one of the first or second aspects of the invention, or a transgenic non-human animal according to the fourth aspect of the invention, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene.

15

In an embodiment according to the sixth aspect of the invention, the method comprises assaying a host cell stably transfected with a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, or a transgenic non-human animal whose cells express such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene.

20

Accordingly there is provided a method of screening for, or monitoring of toxicologically induced stress in a cell or a cell line or a non-human animal, comprising the use of a cell, cell line or non human animal which has been transfected with or carries a nucleic acid construct as described above.

25

30

Toxicological stress may be defined as DNA damage, oxidative stress, post translational chemical modification of cellular proteins, chemical modification of cellular nucleic acids, apoptosis, cell cycle arrest, hyperplasia, immunological changes, effects consequent to changes in hormone levels or chemical modification of hormones, or other factors which could lead to cell damage.

Accordingly, there is also provided a method for screening and characterising viral, bacterial, fungal, and parasitic infection comprising the use of a cell, cell line or non human animal which has been transfected with or carries a nucleic acid construct as described above.

Accordingly, there is additionally provided a method for screening for cancer, inflammatory disease, cardiovascular disease, metabolic disease, neurological disease and disease with a genetic basis comprising the use of a cell, cell line or non human animal which has been transfected with or carries a nucleic acid construct as described above.

In these contexts the cell may be transiently transfected, maintaining the nucleic acid construct as described above episomally and temporarily. Alternatively cells are stably transfected whereby the nucleic acid construct is permanently and stably integrated into the transfected cells' chromosomal DNA.

Also in this context transgenic animal is defined as a non human transgenic animal with the nucleic acid construct as defined above preferably integrated into its genomic DNA in all or some of its cells.

Expression of the peptide tagged lipocalin protein in respect of the fifth aspect of the invention can be assayed for by measuring levels of the lipocalin protein in cell culture medium or purified or partially purified fractions thereof.

Lipocalins are known to be secreted into body fluids and some are known to be eliminated in urine. Expression of the peptide tagged lipocalin protein in accordance with the fourth aspect of the invention therefore can be assayed for by measuring levels of lipocalin secreted into harvestable body fluids. In a preferred embodiment of the invention the body fluid will be urine, but may also be selected from the list including milk, saliva, tears, semen, blood and cerebrospinal fluid, or purified or partially purified fractions thereof.

Detection and quantification of the tagged lipocalins secreted from cultured cells into tissue culture medium or transgenic non-human animal body fluid may be achieved using a number of methods known to those skilled in the art:

1. Immunological methods.

(i) The assay may be an ELISA whereby an antibody or antiserum containing a single or mixture of antibodies recognising either the lipocalin reporter itself or the peptide tag attached to and is used as a capture antibody to coat a microtitre plate or other medium suitable for conducting the assay. The culture medium or body fluid containing the reporter gene product (analyte) is added to the microtitre plate to allow binding of the analyte. Addition of the same antibody or antiserum that has been conjugated to an enzyme, commonly horseradish peroxidase, is used as a second antibody. Addition of a suitable substrate, preferably one producing a colour product following conversion by the enzyme is used to quantify the analyte in proportion to how much second antibody conjugate has been bound.

(ii) Competitive ELISA. In an alternative form the tissue culture medium or the body fluid (analyte) sample containing the tagged lipocalin is bound to a support suitable for conducting the assay. In a separate reaction a limited standard amount of antibody specifically recognising the reporter gene product is added to a separate aliquot of the same and allowed to bind. This is added to the analyte bound to the support to allow remaining free antibody to bind. A second, enzyme conjugated antibody against for example the Fc region of the first antibody is allowed to bind and the colorimetric

readout can be used to quantify the analyte whereby the degree of colour change is inversely proportional to the level of analyte in the sample.

(iii) Western blot analysis

5 Transfected cell homogenates were prepared by incubation of cells in homogenization buffer (140mM NaCl, 50mM Tris-HCl pH7.5, 1mM EDTA, 1% Triton-100) for 30 minutes on ice. Following a brief centrifugation to remove insoluble material the cleared supernatants were assayed for protein content. A volume equivalent to 40µg cell extract and an equal volume of cell medium were subjected to SDS-PAGE and  
10 blotted onto nitrocellulose (Schleicher and Schuell, Dassel, Germany) membrane using a semi-dry blotting apparatus (Bio-Rad, Richmond, CA). The membranes were blocked for 1 hour in blocking buffer (5% NFDM w/v in PBS) then incubated with myc mAb (Invitrogen Life Technologies, Carlsbad, CA) diluted in blocking buffer for 2 hours with continuous agitation. After a series of washes in PBST (PBS plus 0.05%  
15 Tween-20), the membrane was incubated in an anti-mouse antibody conjugated to HRP diluted in blocking buffer for one hour with agitation, and after another series of washes in PBST the HRP activity was developed using an ECL kit (Pierce, Rockford, IL) and captured on autoradiographic film (Kodak).

20 (iv) Fluorescence polarisation. The antibody specifically recognising the reporter lipocalin protein is conjugated with fluorescein and mixed with the analyte produced. This method quantifies the analyte by direct measurement of the amount of antibody-antigen complex present. This method may also be adapted to measure any protein-protein interaction.

25

2. Release of a labelled substrate. E.g. radioactive (CAT) or fluorometric, colorimetric.

Detection of conversion of substrate due to enzymatic activity of the lipocalin reporter protein produced. The nature of substrate conversion may or may not fall into one or  
30 more of the following event categories: Proteolysis, phosphorylation, acetylation, sulphation, methylation



3. Detection of multiple substrates. Where a multiple of lipocalin reporter proteins are used methods suitable for detection of such events could include but not necessarily be limited to:

5

(i) Mass spectrometry

(ii) Nuclear magnetic resonance (NMR)

10 In a preferred embodiment of the invention there is provided a method of detecting a reporter gene activation event, comprising the steps of:

15 1. Transfecting a cell or microinjecting the pronucleus of a fertilised mouse egg with a nucleic acid sequence encoding a lipocalin protein tagged with a peptide or protein as described above in accordance with the first, second, third, or fourth aspects of the invention. Optionally use the microinjected egg or transfected mouse ES cell line;

20 2. Exposing the transfected cell, cell line or transgenic non human animal to a stimulus which may or may not cause a change in metabolic status resulting alteration in gene expression; and.

25 3. Using a suitable assay to determine the level expression of the tagged lipocalin reporter, for example using detection methods such as ELISA, RIA, Mass spectrometry, NMR, telemetric methods.

In step (1), the detectable lipocalin protein may be a heterologous protein to the cell in which the nucleic acid construct is expressed. Such an "untagged" lipocalin reporter protein may not therefore need a peptide or protein tag for detection.

30

Methods and uses in accordance with the present invention offer significant advances in investigating any area in which modified gene expression plays a significant role. Such peptide tagged lipocalin genes will be of use in cells and transgenic animals to detect activity of selected genes. Specific applications include but are not restricted to:

5

1. Providing a rapid and robust *in vivo* screening system for assessing the potential toxic effects of chemicals.
2. Provide information on the mechanism of toxicity. Such information could be used to eliminate compounds from a selection process or suggest possible modifications to a compound.
3. Provide information on the effect of combinations of compounds.
4. Allow monitoring of variation in reporter gene expression over time by measuring levels of reporter(s) in urine at different time intervals.
5. Assessment of changes in gene expression associated with pathogenic infection.
6. Assessment of changes in gene expression associated with neurological, cardiovascular and metabolic diseases.
7. Assessment of changes in gene expression associated with cancer.
8. Provide information allowing validation of drug target selection e.g. by matching reporter expression profile to actions of toxins whose mechanism is defined and understood.
9. Use for evaluating compounds as therapeutic strategies aimed at reversing a toxic, metabolic, or degenerative phenotype.
10. Assessment of changes in gene expression resulting from environmental and/or behavioural changes.

10

15

20

25

Preferred features for the second and subsequent aspects of the invention are as for the first aspect *mutatis mutandis*.

30

The present invention will now be described with reference to the following examples which are present for the purposes of illustration only and should not be construed as

being limited with respect to the invention. Reference in the application is also made to a number of drawings in which:

5

FIGURE 1 shows the position of the peptide tag at the amino terminal or carboxy terminal or inserted internally with respect to the amino acid sequence of the lipocalin reporter protein

FIGURE 2 shows the plasmid map for p $\alpha$ 1ATBLG

10

FIGURE 3 shows the plasmid map for pXC3'MycMUP

FIGURE 4 shows the plasmid map for pcDNA.3'mycMUP

15

FIGURE 5 shows the plasmid map for pX4T.3'MYCMUP

FIGURE 6 shows the results of expression of Myc tagged MUP

20

FIGURE 7 shows the DNA and amino acid sequences of the MUP clone Mmup9a. The 18 amino acid secretion signal peptide is shown in bold (amino acid residues 1 to 18).

25

FIGURE 8 shows the DNA and amino acid sequence of the recombinant mMUP reporter molecule. The protein contains a sixteen amino acid N-terminal addition, comprising of 6 amino acids from the pGEX vector (italics – amino acid residues 1 to 6) and the c-myc epitope (shown in bold – amino acid residues 7 to 16).

30

FIGURE 9 shows the DNA and amino acid sequence of the recombinant BLGm reporter molecule. The protein contains a six amino acid N-terminal addition from the pGEX vector (italics – amino acid residues 1 to 6) and the C-terminal c-myc epitope (bold – amino acid residues 170 to 179).

FIGURE 10 shows (a) Western blot of GST-BLGm fusion protein. Lanes 1 to 6 show fractions eluted from a glutathione-agarose column. Lane C, mMUP protein control. (b) Western blot of GST-MUPm fusion protein. Lanes 1 to 7 show fractions eluted from glutathione-agarose column. Blots were probed using 9E10 anti-myc antibody directly conjugated to HRP (Roche).

FIGURE 11 shows Western blot analysis of urine samples (15 $\mu$ l) collected from mice, following injection with either (A) vehicle or recombinant mMUP (2.5mg/kg); or (B) recombinant mMUP (5 and 10mg/kg). Blots were probed with anti-myc antibody. Uninjected recombinant GSTmMUP (~ 45kDa, open arrow) was included as a positive control (right hand lane). The closed arrow indicates the position of the ~18kDa mMUP control band.

FIGURE 12 shows Western blot analysis of urine samples taken at various time points (in hours) and plasma (P) at 24 hours from mice that had been injected with recombinant GST-BLGm and GST-mMUP. Blots were probed with an anti-GST antibody. Arrow indicates the expected size of the band corresponding to GST-mMUP protein.

FIGURE 13 shows the 3-dimensional solution structure of MUP. The antiparallel  $\beta$ -sheets are shown in brown, and the loop regions in blue. The EF loop is marked, as is the FG loop. Red lines indicate amino acid positions where the internal restriction site additions were made.

FIGURE 14 shows antibody detection of epitope tagged MUP reporter proteins: (A) Haemagglutinin (HA) tagged MUP protein was expressed in *E. coli*, and extracts from induced (Lane 1) and uninduced (Lane 2) cells analysed by western blotting using an anti-HA antibody (3F10, Roche) HRP-conjugated second antibody and ECL detection (Amersham). Lane 3 contains molecular size markers. A specific band of the expected size is seen for the HA-tagged

GST-MUP fusion protein; (B) ERB tagged MUP protein was expressed in *E. coli* and extracts from induced (Lane 2) and uninduced (Lane 3) cells analysed by western blotting using an anti-ERB antibody (ICRF Technology), HRP-conjugated second antibody and ECL detection (Amersham). (Lane 1 molecular size markers). A specific band of the expected size is seen for the ERB-tagged GST-MUP fusion protein. Extensive photo-bleaching is seen in Lane 1, due to the amount of protein present.

FIGURE 15 shows modified MUP proteins produced from the pSecTag vector. The various modifications made to the wild-type MUP protein sequence (overlined region) are shown: the Igk signal peptide leader, which is cleaved during processing (++++); the c-myc epitope tag (underlined); the iTag insertion sequence in the FG loop (italics); and the Clone 100 epitope tag (bold), and the other C- and N-terminal modifications and additions.

FIGURE 16 shows results of pSecTag MUP constructs that were transfected into A2780 cells using Fugene, and the medium (50µl) directly examined for secreted protein by Western blotting, using anti-myc antibody 9E10. Lane C, recombinant mMUP control; Lane 1, pSML.ic100; Lane 2, pSML; Lane 3, pSM; Lane 4, pSecmMUP. Several protein bands are present in the pSecmMUP medium, due to the presence of multiple start sites in the 5'-region of this construct.

FIGURE 17 shows analysis of mouse urine containing either GST or GST-mMUP, together with GST or GST-mMUP in phosphate buffered saline (PBS) for GST enzymic activity. The concentration of all proteins was 100µg/ml. The graph shows GST enzymic activity, as absorbance (340nm) versus time, relative to the absorbance at the 30 second timepoint.

FIGURE 18 shows the nucleotide sequence for ovine betalactoglobulin (BLG) (accession no. X12817), available from [www.ncbi.nlm.nih.gov/entrez](http://www.ncbi.nlm.nih.gov/entrez),

published by Harris,S *et al Nucleic Acids Res.* **16** (21), 10379-10380 (1988);  
Watson,C.J. *et al Nucleic Acids Res.* **19** (23), 6603-6610 (1991). The signal  
peptide is coded for by residues 842 to 895 and mature protein from 6 exons at  
residues 896..937,1602..1741,2586..2659,3772..3882,4551..4655, 4869..4882

5

FIGURE 19 shows the amino acid sequence for ovine betalactoglobulin (BLG)  
coded for by the nucleotide sequence of Figure 16.

FIGURE 20 shows the cDNA encoding the mRNA of murine major urinary  
protein 1 (Mup1), (Accession no. NM 031188), ), available from  
[www.ncbi.nlm.nih.gov/entrez](http://www.ncbi.nlm.nih.gov/entrez), published Lucke *et al Eur. J. Biochem.* **266** (3),  
1210-1218 (1999); Abbate, *et al J. Biomol. NMR* **15** (2), 187-188 (1999);  
Ferrari *et al FEBS Lett.* **401** (1), 73-77 (1997); Held, *et al Mol. Cell. Biol.* **7**  
(10), 3705-3712 (1987); Bennett *et al J. Cell Biol.* **105** (3), 1073-1085 (1987);  
Shahan *et al Mol. Cell. Biol.* **7** (5), 1938-1946 (1987); Clark *et al EMBO J.* **4**  
(12), 3167-3171 (1985); Clark, *et al EMBO J.* **4** (12), 3159-3165 (1985);  
Ghazal *et al Proc. Nat'l. Acad. Sci. USA.* **82** (12), 4182-4185 (1985); Kuhn *et al Nucleic Acids Res.* **12** (15), 6073-6090 (1984); Clark *et al EMBO J.* **3** (5),  
1045-1052 (1984); Krauter *et al J. Cell Biol.* **94** (2), 414-417 (1982); coding  
sequence from residues 112..654.

20

FIGURE 21 shows the amino acid sequence for murine major urinary protein  
coded for by the nucleotide sequence of Figure 18.

FIGURE 22 shows the cDNA sequence encoding the mRNA of rat alpha-2-u  
globulin (accession no. M27434), available from  
[www.ncbi.nlm.nih.gov/entrez](http://www.ncbi.nlm.nih.gov/entrez), published by Roy *et al*  
*J. Steroid Biochem.* **27** (4-6), 1129-1134 (1987)

25

FIGURE 23 shows the GST coding sequence derived from pGEX6p-1. The GST coding sequence is nucleotide residues 241-917. The residues highlighted in bold

5	<b>Leu</b>	<b>Glu</b>	<b>Val</b>	<b>Leu</b>	<b>Phe</b>	<b>Gln</b>	<b>Gly</b>	<b>Pro</b>
	ctg	gaa	gtt	ctg	ttc	cag	ggg	ccc

represent the PreScission<sup>TM</sup> Protease cleavage recognition sequence position 918-938. The protease cleavage site allows for the production of cleaved myc-tagged proteins from the GST fusion proteins as described in Example 6.

#### **Example 1: Preparation of p $\alpha$ 1ATBLG**

The  $\alpha$ 1AT promoter (350bp) was excised from  $\alpha$ 1AT/CAT (Yull *et al Transgenic Res.* 4 70-74 (1995)) as a HindIII SmaI fragment and inserted into pBlue $\alpha$ 1AT. Digestion of this with EcoRV and XhoI allowed direct insertion of the  $\alpha$ 1AT promoter into pXen6.S (Simon Temperley, CXR Biosciences) digested with the same enzymes. The microinjection fragment was purified after digestion of the plasmid with p $\alpha$ 1ATBLG (shown in Figure 2).

#### **Example 2: Preparation of pX4T3'MycMUP**

A XhoI/KpnI fragment encoding amino terminal c-Myc tagged mouse MUP was inserted into pXAM4 (CXR Biosciences) effectively placing it under the control of the CMV promoter. pXAM4 was previously constructed by inserting a PCR generated fragment containing the CMV promoter as a BamH1-XhoI fragment into a pSP72 (Promega) multiple cloning site which had been modified by addition of a linker which added restriction sites allowing insertion of additional fragments downstream of the CMV promoter sequence.

#### **Example 3: Preparation of pXC3'MycMUP**

A 2.5kb DNA fragment encompassing the murine Cyp1A1 promoter and upstream sequences was inserted into SstII/XhoI digested pX4T.3'MycMUP (Thomas

McCartney, CXR Biosciences) to engineer a reporter vector capable of expressing COOH terminally c-Myc tagged MUP upon induction of the CYP1A1 promoter using a suitable inducing agent, if the construct is used to transfect a suitable cell line or to generate a transgenic animal.

5

**Example 4: pcDNA.3'MycMUP**

A DNA fragment encompassing the COOH terminally c-Myc tagged MUP was excised from pX4T.3'Myc (Thomas McCartney, CXR Biosciences) to engineer an expression vector capable of constitutive expression of c-Myc tagged MUP if used to transfect a suitable cell line or to generate a transgenic animal.

10

**Example 5: Expression of Myc-MUP**

Constructs were tested by transient transfection of a 90% confluent monolayer of Hepa1-6 cells in a T-25 flask using 6ug of DNA in accordance with the protocol supplied with Lipofectamine transfection reagent (Invitrogen).

15

Cells and 5ml of medium were harvested 48 hours post-transfection. Total protein from the cell pellets was obtained using 1ml TRI reagent (Sigma) per pellet in accordance with directions. Cellular protein was further purified using the PlusOne SDS-PAGE Clean-Up Kit (Amersham) in accordance with directions. Correspondingly, protein was purified from 100µl samples of growth medium from each transfected cell batch using the PlusOne SDS-PAGE Clean-Up Kit in accordance with directions.

20

Cell extracts and culture medium from Hepa1 cells transfected with constructs designed to constitutively express NH3 and COOH terminally Myc tagged MUP coding sequences from the CMV promoter (2<sup>nd</sup> and 3<sup>rd</sup> lanes from left respectively in both left and right panels; plasmids X4T5'MycMUP and X4T3'MycMUP respectively) were subject to SDS-PAGE. Results shown in Figure 6

25

30



Western blot analysis by probing with antibody against c-Myc showed the presence of COOH terminally tagged MUP in both cell extract and medium of Hepa1 cells (3<sup>rd</sup> lane from left in both left and right hand panels). Results shown in Figure 6

5 25% of the total cellular protein samples and the entire protein sample derived from the growth medium were analysed by SDS-PAGE followed by western blot in accordance with equipment manufacturer's (BIO-RAD) directions. The blot was probed using the murine monoclonal Anti-Myc antibody 9E10 (Sigma) in conjunction with anti-mouse Ig HRP conjugated antibody (Amersham). Visualisation was  
10 performed using ECL reagent (Amersham) in accordance with directions.

**Example 6: Production of recombinant epitope tagged lipocalin proteins**

Two candidate lipocalin family members, ovine beta-lactoglobulin (BLG) and mouse major urinary protein (MUP) have been shown to function as excreted reporter  
15 molecules. This has been achieved by introducing recombinant protein to mice via intravenous injection into the tail vein, followed by analysis of urine and plasma by western blotting.

To expand the application of a secreted/excreted reporter, it is possible to modify the  
20 reporter protein by the addition of specific epitope tag. This should allow a single reporter protein backbone to report on a number of specific events within a single system. We have demonstrated the ability to introduce additional amino acid motifs containing epitope tags at the N-terminus, the C-terminus and at several internal loop  
25 positions of the lipocalin reporter protein.

Recombinant MUP and BLG were expressed in *E.coli* using the pGEX vector system (Amersham Bioscience), which expresses all inserted sequences as a C-terminal fusion  
30 protein with vector encoded glutathione-S-transferase (GST). GST may be removed from the inserted fusion partner via a specific proteolytic cleavage site located at the C terminal end of GST.

A MUP clone, Mmup9a, was derived from mouse liver RNA by RT-PCR, and the identity confirmed by sequencing (Figure 7). This clone, Mmup9a, is almost identical (536/537 bases) to the MusMup1 type I MUP clone (M16355, Genbank). The MUP coding sequence, minus the N-terminal 18 amino acid signal peptide, was rederived from clone Mup9a, by PCR as an NcoI-XhoI fragment, and cloned into the *E. coli* expression vector pGEX-6PB (derived from pGEX-6P-1, Amersham Bioscience) to produce pGEX-MUP. A synthetic linker oligonucleotide was then used to add the c-myc epitope sequence, as an NcoI-NcoI fragment, to the 5'-end of the MUP coding sequence to give pGEX-mMUP.

pCD3'mycBLG, containing the BLG precursor protein cDNA fused with a C-terminal myc epitope tag, was constructed from the BLG cDNA clone pBlacD (Roslin Institute). The C-terminal myc-tagged BLG coding sequence, minus the 18 amino acid signal peptide, was derived by PCR from pCD3'mycBLG (containing the BLG precursor protein cDNA fused with a C-terminal myc epitope tag) and cloned directly into pGEX-6PB, to produce pGEX-BLGm.

Constructs pGEX-mMUP and pGEX-BLGm were then used to produce recombinant GST fusion proteins in *E. coli* DH5a, and the GST fragments removed by protease treatment (PreScission Protease, Amersham Bioscience) to generate N-terminally myc-tagged MUP (mMUP – Figure 8) and C-terminally myc-tagged BLG (BLGm – Figure 9) lipocalin reporter proteins respectively. Purification of recombinant protein was achieved via affinity chromatography following the manufacturers recommended protocols (Amersham Bioscience).

Both the GST fusion precursors and the cleaved myc-tagged protein products were recognised on western blots (Figure 10) using horseradish peroxidase (HRP) directly conjugated to an anti-myc antibody (9E10, Roche) and ECL chemiluminescent detection kit (Amersham Bioscience).

**Example 7: *In vivo* excretion of MUP and BLG epitope tagged lipocalin reporter proteins**

In order to demonstrate the excretion of epitope-tagged MUP and BLG reporter proteins, recombinant epitope-tagged mMUP lipocalin protein was injected i.v. into male CD1 mice (3 doses, 2.5mg/kg, 5mg/kg and 10mg/kg with 3 mice per group, via the tail vein). A control group were also injected with the vehicle solution (isotonic sterile saline). After injection, urine samples were collected from mice, by scruffing, at approximately 30 minute time intervals over a 6h period. Mice were sacrificed after 24 hours and urine and serum samples taken.

Urine was analysed by SDS PAGE, followed by western transfer to nitrocellulose membrane (Hybond ECL, Amersham Bioscience) and probed with HRP-conjugated anti-myc antibody (9E10, Roche) and detected with the ECL detection kit (Amersham Bioscience).

The results of this analysis are shown in Figure 11. From this, it can be seen that the majority of MUP protein was detected in the first two or three samples i.e. within 2h post injection. Urine samples collected at later time points and serum taken from animals after 24h did not contain detectable MUP reporter protein. These data clearly demonstrate that exogenous mMUP in the bloodstream of mice is eliminated rapidly and efficiently in the urine.

Western blot analysis was repeated on all samples after three weeks to determine the stability of recombinant protein in mouse urine upon storage at  $-20^{\circ}\text{C}$ . The results were similar to those initially obtained (data not shown), showing no appreciable decrease in sensitivity, demonstrating that mMUP protein is able to withstand long term freezer storage and thawing.

In order to demonstrate the application of lipocalin reporter proteins containing a large epitope tag (GST), tail vein injections were conducted subsequently with recombinant

myc-tagged lipocalin-GST fusion proteins (GST-BLGm and GST-mMUP). Each protein was injected at a dose of 5mg/kg. Samples were fractionated by SDS PAGE and analysed by western blotting. Blots were probed using an anti-GST antibody (Sigma), HRP-conjugated anti-rabbit secondary antibody (Jackson ImmunoResearch) and ECL detection kit (Amersham Bioscience). Urine samples collected early and late after IV injection and plasma from a terminal bleed were included in the analysis. From Figure 12, it can be seen that GST-BLGm and GST-mMUP proteins are detected in urine samples throughout the sampling period and also in plasma taken from the animal after 24 hours.

The difference in excretion profiles between GST-mMUP fusion protein (45kDa mol. weight) and mMUP (~18kDa mol. weight) could reflect a difference in the physiological processing of the former (e.g. reabsorption via the kidney into the plasma) or less efficient excretion. A choice of non-invasive reporter molecule whose excretion characteristics differ in such a manner could prove useful, depending on whether a persistent readout or a more rapidly decaying, and thus responsive, signal are required.

#### **Example 8: Epitope tagging of lipocalin reporter protein**

MUP and BLG lipocalin reporter proteins have been successfully tagged with N- and C-terminal tags (above data for GST and c-myc tags). Internal loop positions within the MUP protein have also been used to introduce the peptide epitope sequences. Several potential positions for the introduction of epitope tags were chosen, from the MUP protein structure (Figure 15), as being in external loops. The initial position chosen to introduce a tag corresponded to a site within the EF loop of BLG protein that had previously been used to introduce a kinase recognition site. This had utilised a *Clal* restriction site in the BLG gene, however there is no corresponding restriction site in the MUP gene. Consequently, the Mup cDNA sequence was modified by the introduction of a) an *AvrII-ApaI-SbfI* linker fragment into the sequence coding for EF loop region and b) a *SpeI-EcoRI-NsiI* linker fragment at the 3' end of the coding sequence. The particular restriction site combinations were chosen since they would

generate compatible overhanging ends, for the insertion of adapter oligonucleotides containing epitope sequences. The MUP 5'-coding region from position 10 to 300, together with an additional GATGCGGTACCACCATGGTGTCTAGACTGCAG 5'-sequence (containing a Kozak signal, start codon and NcoI-KpnI-XbaI-PstI linker) and  
 5 an additional CCTAGGC sequence (containing an AvrII restriction site) was generated by PCR. The corresponding MUP 3'-region from position 301 to 540, together with an additional TGCCTAGGGCCCTGCAGGGTA 5'-sequence (containing an AvrII-ApaI-SbfI linker) and ACTAGTGAATTCATGCATTGAGCTAGCCATC 3'-sequence (containing an SpeI-EcoRI-NsiI-NheI linker and stop codon was generated by PCR.  
 10 Ligation of these two fragments, at the common AvaII site generated the required modified MUP coding sequence, on a NcoI-NheI fragment.

Restriction digest with either AvrII/SbfI (internal EF loop) or SpeI/NsiI (C-terminus) results in an identical pattern of overhanging ends, to which double stranded  
 15 oligonucleotide linkers, of the general form:

CTAG N (NNN)<sub>x</sub> N TGCA

N (NNN)<sub>x</sub>

where x is a multiple of 3, that contain an epitope tag, can anneal.

20 MUP lipocalin reporter proteins have also been produced, in which the epitope has been introduced into the FG loop position. This has been accomplished by the insertion of a *HindIII*-*BamHI*-*EcoRI* linker fragment into the MUP coding sequence at the FG loop position. This has allowed the insertion of adapter oligonucleotides containing epitope sequences into the *HindIII*/*EcoRI* sites. The MUP coding sequence,  
 25 from position 1 to 348, together with an additional GGTACCACC 5'-sequence (containing a KpnI restriction site and Kozak sequence) and an additional AAGCTTGGAACCGGATCC 3'-sequence (containing *HindIII*-*BamHI* sites) was generated by PCR, as was the corresponding MUP coding sequence from position 349 to 540, together with an additional GGATCCTCTTCAGAATTC 5'-sequence  
 30 (containing *BamHI* and *EcoRI* restriction sites) and an additional GAGCAGAACTCATCTCTGAAGAGGATCTGTGAGCTAGC 3'-sequence

(containing the c-myc GluGlnLysLeuIleSerGluGluAspLeu epitope tag , stop codon and NheI restriction site). Ligation of the two fragments, at the BamHI site generated the modified MUP coding sequence, on a NcoI-NheI fragment.

- 5 Restriction digest with HindIII/EcoRI results in overhanging ends, to which double stranded oligonucleotide linkers, of the general form:

AGCT T (NNN)<sub>x</sub> G

A (NNN)<sub>x</sub> C TTAA

where x is a multiple of 3, that contain an epitope tag, can anneal.

10

Epitopes that have been inserted into the FG loop, by this method, include:

	Haemagglutinin	(YPYDVPDYA)
	Clone100	(NVRFSTIVRRRA)
15	rab11a	(KQMSDRRENDMSPS)
	DOB	(SGNEVSRAVLLPQSC)
	SG11	(SSLSTNPAAVAATSANL)
	erbB4	(RSTLQHPDYLQEYST)
	ARF	(VSTLLRWERFPGHRQA)
20	RYK	(KFQQLVQCLTEFHAALGAYV)
	WILPEP1	(QEQCQEVWRKRVISAFKSP)
	HAF10	(RLSDKTGPVAQEKS)

25 MUP coding sequences, containing these epitope tag sequences, were expressed in *E. coli* as GST fusion precursor proteins, and cleaved tagged MUP proteins, using the pGEX expression system (Amersham Biosciences).

30 FG loop modified MUP coding sequence was cloned into NcoI-NotI cut pGEX6P vector to generate pGSLM, that contains the MUP coding region downstream of the GST coding sequence and Precissionase cleavage site.

Individual epitope tags were introduced by HindIII/EcoRI digestion and annealing of epitope containing oligonucleotide linkers.

5 *E. coli* strain TOP10 (Invitrogen) was transformed with the pGSLM-tag construct, using the manufacturers standard protocols.

10 The resultant transformed bacterial strains were grown in shaking flask culture to an OD<sub>600</sub> of 0.5-0.6. Once the optimal turbidity was attained a small sample was removed as a control and IPTG added to the remaining culture to a final concentration of 0.5mM. Both the control sample (uninduced) and the induced cultures were grown for a further 2-3 hours. After the final growth step 0.25ml and 0.5ml of uninduced and induced culture respectively was spun down and resuspended in 100ul 6xGLB and 5-10ul of each run on NuPAGE gels (Invitrogen) to ascertain whether induction had taken place and the fusion product was the correct size.

15 The remaining induced culture (3.2L total for large preps) was spun down, lysed and cell debris removed by centrifugation. GST fusion proteins from cleared lysate were allowed to bind to Glutathione-Agarose beads (SIGMA) for 0.5-1 hour at +4°C. The protein/bead slurry was poured onto a gravity flow column and the resultant gel bed washed thoroughly with lysis buffer to remove bacterial proteins. Fusion proteins were then eluted from the gel bed with excess Glutathione (10mM in 50mM Tris pH8.0). Samples were checked via SDS-PAGE and Immunodetection before proceeding to cleave and purify the tagged MUP protein from the GST fusion. The purified eluate was dialysed in cleavage buffer (4 x 3 hours) and then incubated for 16 hours with at least 60 units of Precissionase at +4°C. The digested protein was then added to a gravity flow column containing fresh Glutathione-Agarose beads which bound the GST and Precissionase allowing the elution of the cleaned, digested tagged MUP protein. The eluate was re-added twice to ensure complete removal of contaminating proteins and then concentrated using Centricon-P20 columns (Millipore) to give the final protein solution.

20

25

30

Extracts from induced and uninduced cells were analysed by western blotting for the presence of the relevant tagged MUP protein, using an epitope-specific monoclonal antibody. Some representative results are shown in Figure 14.

5     **Example 9: *In vivo* expression and secretion of lipocalin reporter proteins**

It is possible that modifying the protein sequence, by the introduction of epitopes, would affect protein folding or secretion. In order to examine this, we have expressed the modified MUP proteins in murine Hepa1-6 hepatoma cells and in human A2780 ovarian carcinoma cells.

10

MUP lipocalin reporter sequences, containing internal modifications at protein loop positions, were cloned into the pSecTag2 vector (Invitrogen). This vector contains a murine Ig Kappa signal peptide, a 3'-c-myc and His tag, and is designed to express tagged secreted proteins in mammalian cells.

15

In this way, 4 MUP reporter constructs, coding for proteins that contain epitope tag modifications at either the N-terminus, the C-terminus or at the internal FG loop position, were created (Figure 15).

20

The DNA constructs were transfected into both murine Hepa1-6 hepatoma cells and human A2780 ovarian carcinoma cells, using Fugene transfection reagent (Invitrogen). After 72h, medium was collected and analysed for the presence of secreted protein by western blotting. A typical blot is shown in Figure 16.

25

The results demonstrate that MUP lipocalin reporter proteins, containing multiple modifications, are properly folded and secreted from mammalian cells.

**Example 10: Enzymic detection of lipocalin protein**

30

To demonstrate the detection of a lipocalin reporter by means of an epitope tag that contains enzymic activity, we have examined the GST enzymic activity of the GST-tagged MUP lipocalin reporter protein.



Mouse urine, that had previously been spiked with GST-mMUP protein (100µg/ml) was analysed for GST enzymic activity using a colorimetric assay (GST-Tag Kit, Novagen). The assay was performed according to the manufacturers recommended protocol, using a Hitachi-U3010 spectrophotometer and Hitachi UV Solutions Version 1.2 software. Absorbance was measured at 340nm. Readings were taken every 30 seconds for 300 seconds

The results show that GST-mMUP lipocalin reporter protein can be efficiently detected in mouse urine by means of GST enzymic activity (Figure 17). The activity of the GST-mMUP protein, in both urine and PBS, is similar to that of GST protein itself.

**Example 11: Expression of epitope tagged lipocalin reporter proteins in transgenic animals**

Transgenic animals are generated using one of several standard methods including pronuclear injection (Gordon and Ruddle, *Science* 214, 1244-1246 (1981)), blastocyst injection of transfected cells (Smithies *et al.*, *Nature* 317, 230-234 (1985)) or using viral vectors (Lois *et al.*, *Science* 295, 868-872 (2002); Pfeifer *et al.*, *Proc. Natl. Acad. Sci. USA* 99, 2140-2145 (2002)). The transgene comprises DNA fragments including a promoter sequence driving an open reading frame encoding a tagged-lipocalin.

For example transgenes contain the mouse Cyp1a1 promoter sequence driving expression of myc epitope tagged MUP or BLG reporters, as follows:

**pXC3'mycMUP.** A 2.4Kb fragment encompassing the murine Cyp1a1 promoter was derived by PCR from murine genomic DNA. This was cloned into the vector pXen5s (CXR Biosciences) as a *SpeI/XhoI* fragment to yield the vector pXen5Cyp. The Cyp1a promoter was subsequently moved from pXen5Cyp into the vector pXen4.3'mycMUP (CXR Biosciences) as an *SstII/XhoI* fragment replacing the CMV promoter contained in this vector. The resultant vector pXC3'mycMUP contains a C-terminally tagged MUP reporter running under the control of the murine Cyp1a1 promoter.

pXC3'mycBLG. The BLG reporter was amplified from the vector pBLacD (Roslin Institute) by PCR, adding flanking *XhoI* and *KpnI* sites and inserting a C-terminal Myc epitope tag. This fragment was digested *XhoI/KpnI* and used to replace the MUP reporter in *XhoI/KpnI* digested pXC3'mycMUP vector. The resultant vector pXC3'mycBLG contains a C-terminally tagged BLG reporter running under the control of the murine *Cyp11a1* promoter.

Positive transgenic animals are identified by analysis of DNA (Whitelaw *et al.*, *Transgenic Res.* 1, 3-13 (1991)) and bred to generate transgenic lines. Transgenic animals are exposed to stress, for example by drug administration, and blood and urine collected over time. Samples collected pre- and post-insult are analysed for the presence of the tagged-lipocalin by standard methods, including Western blot and ELISA. Depending on the specific insult or inducing agent an increase or decrease in reporter activity are detected.

Transgenes may also be refined to allow expression in specific cells, for example through the DNA recombination based strategies (Fiering *et al.*, *Proc. Natl.Acad.Sci.USA* 90, 8469-8473 (1993); Gu *et al.*, *Cell* 73, 1155-1164 (1993)).

Alternatively DNA promoter-reporter constructs are introduced into somatic cells of an animal. This could be achieved through the use of adenovirus (Lai *et al.*, *DNA Cell Biol.* 21, 895-913 (2002), other viral vector methods (Logan *et al.*, *Curr. Opin. Bioetchnol.* 13, 429-436 (2002)) or by non-viral methods including the direct introduction of naked DNA (Niidome and Huang, *Gene Ther.* 9, 1647-1652 (2002)).

**CLAIMS**

1. A nucleic acid construct comprising (i) a nucleic acid sequence encoding a member of the lipocalin protein family, and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues

5

2. A nucleic acid construct as claimed in claim 1, in which the lipocalin is selected from the group consisting of: ovine betalactoglobulin (BLG) (accession No. X12817), murine major urinary protein (MUP) (accession No. NM 031188) and rat  $\alpha$ -2-urinary globulin ( $\alpha$ -2u) (accession number M27434).

10

3. A nucleic acid construct as claimed in claim 1 or claim 2, in which peptide sequence is an epitope.

4. A nucleic acid construct as claimed in claim 3, in which the epitope is selected from the group consisting of EQKLISEEDL, GKPIPNPLLGLDST, YPYDVPDYA, NVRFSTIVRRRA, KQMSDRRENDMSPS, SGNEVSRAVLLPQSC, SLSYTNPAVAATSANL, RSTLQHPDYLQEYST, VSTLLRWERFPGHRQA, KFQQLVQCLTEFHAALGAYV, QEQCQEVWRKRVISAFKSP, and RLSDKTGPVAQEKS

20

5. A nucleic acid construct as claimed in any one of claims 1 to 4, in which the construct additionally comprises a promoter element upstream of the (i) a nucleic acid sequence encoding a member of the lipocalin protein family, and (ii) and nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues.

25

6. A nucleic acid construct as claimed in claim 5, in which the promoter element may be selected from one of the following groups consisting of :

(i) c-myc, p21/WAF-1, MDM2, Gadd45, FasL, GAHSP40, TRAIL-R2/DR5, BTG2/PC3;

30

(ii) MnSOD, CuZnSOD, I $\kappa$ B, ATF4, xanthine oxidase, COX2, iNOS, Ets-2, FasL/CD95L,  $\gamma$ GCS, ORP150.

(iii) Lrg-21, SOCS-2, SOCS-3, PAI-1, GBP28/adiponectin,  $\alpha$ -1 acid glycoprotein, metallothioneine I, metallothioneine II, ATF3, IGFbp-3, VEGF and HIF1 $\alpha$ .

(iv) Gadd 34, GAHSP40, TRAIL-R2/DR5, c-fos, CHOP/Gadd153, APAF-1, Gadd45, BTG2/PC3, Peg3/Pwl, Siah1a, S29 ribosomal protein, FasL/CD95L, tissue transglutaminase, GRP78, Nur77/NGFI-B, CyclophilinD, p73 and Bak.

(v) a promoter from a xenobiotic metabolising cytochrome p450 enzymes from the 2A, 2B, 2C, 2D, 2E, 2S, 3A, 4A and 4B gene families.

(vi) a synthetic promoter sequence comprised of a minimal eukaryote consensus promoter operatively linked to one or more response elements selected from the group consisting of the aryl hydrocarbon (Ah)/Ah nuclear translocator (ARNT) receptor response element, the antioxidant response element (ARE), the xenobiotic response element (XRE).

7. A nucleic acid construct comprising a stress inducible promoter operatively isolated from a nucleic acid sequence encoding a member of the lipocalin protein family by a nucleotide sequence flanked by nucleic acid sequences recognised by a site specific recombinase, or by insertion such that it is inverted with respect to the transcription unit encoding a member of the lipocalin protein family, in which the construct additionally comprises a nucleic acid sequence comprising a tissue specific promoter operatively linked to a gene encoding the coding sequence for the site specific recombinase.

8. A nucleic acid construct as claimed in claim 7, in which the site specific recombinase sequences are two *loxP* sites of bacteriophage P1.

9. A host cell transfected with a nucleic acid construct according to any one of claims 1 to 8.

5 10. A transgenic non-human animal in which the cells of the non-human animal express the protein encoded by the nucleic acid construct according to any one of claims 1 to 8.

10 11. A transgenic non-human animal as claimed in claim 10, in which the non-human animal is a mammal

12. A transgenic non-human mammal as claimed in claim 11, in which the mammal is a mouse


15 13. The use of a nucleic acid construct according to any one of claims 1 to 8 for the detection of a gene activation event resulting from a change in altered metabolic status in a cell *in vitro* or *in vivo*.

20 14. A use as claimed in claim 13, in which the gene activation event is the induction of toxicological stress, metabolic changes, or disease, including a disease state that is the result of viral, bacterial, fungal or parasitic infection.

25 15. The use of a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, for the detection of a gene activation event resulting from a change in altered metabolic status in a cell *in vitro* or *in vivo*.

30 16. A use as claimed in claim 15, in which the gene activation event is induction of toxicological stress, metabolic changes, or disease, including a disease that is the result of viral, bacterial, fungal or parasitic infection.

17. A method of detecting a gene activation event in a cell *in vitro* or *in vivo*, comprising assaying a host cell stably transfected with a nucleic acid construct in accordance with any one of claims 1 to 8, or a transgenic non-human animal according to any one of claims 10 to 12, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene.
18. A method of detecting a gene activation event in a cell *in vitro* or *in vivo*, comprising assaying a host cell stably transfected with a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, or a transgenic non-human animal whose cells express such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene.
19. A method of screening for, or monitoring of toxicologically induced stress in a cell or a cell line or a non-human animal, comprising the use of a cell, cell line or non human animal which has been transfected with or carries a nucleic acid construct according to any one of claims 1 to 8.
20. A method for screening and characterising viral, bacterial, fungal, and parasitic infection comprising the use of a cell, cell line or non human animal which has been transfected with or carries a nucleic acid construct according to any one of claims 1 to 8.
21. A method for screening for cancer, inflammatory disease, cardiovascular disease, metabolic disease, neurological disease and disease with a genetic basis comprising the use of a cell, cell line or non human animal which has been transfected with or carries a nucleic acid construct according to any one of claims 1 to 8.



Tagged lipocalin reporter expression vector

FIG. 1

2 / 15




FIG. 2




FIG. 3



3 / 15




FIG. 4





FIG. 5

4 / 15



5 / 15

MetLysMetLeuLeuLeuLeuCysLeuGlyLeuThrLeuValCysValHisAlaGluGlu  
1 ATGAAGATGCTGCTGCTGCTGTGTTGGGACTGACCCTAGTCTGTGTCCATGCAGAAGAA  
AlaSerSerThrGlyArgAsnPheAsnValGluLysIleAsnGlyGluTrpHisThrIle  
61 GCTAGTTCTACGGGAAGGAACCTTTAATGTAGAAAAGATTAATGGGGAATGGCATACTATT  
IleLeuAlaSerAspLysArgGluLysIleGluAspAsnGlyAsnPheArgLeuPheLeu  
121 ATCCTGGCCTCTGACAAAAGAGAAAAGATAGAAGATAATGGCAACTTTAGACTTTTTCTG  
GluGlnIleHisValLeuGluLysSerLeuValLeuLysPheHisThrValArgAspGlu  
181 GAGCAAATCCATGTCTTGGAGAAATCCTTAGTTCTTAAATTCCATACTGTAAGAGATGAA  
GluCysSerGluLeuSerMetValAlaAspLysThrGluLysAlaGlyGluTyrSerVal  
241 GAGTGCTCGGAATTATCTATGGTTGCTGACAAAACAGAAAAGGCTGGTGAATATTCTGTG  
ThrTyrAspGlyPheAsnThrPheThrIleProLysThrAspTyrAspAsnPheLeuMet  
301 ACGTATGATGGATTCAATACATTTACTATACCTAAGACAGACTATGATAACTTTCTTATG  
AlaHisLeuIleAsnGluLysAspGlyGluThrPheGlnLeuMetGlyLeuTyrGlyArg  
361 GCTCATCTCATTAAACGAAAAGGATGGGGAACCTTCCAGCTGATGGGGCTCTATGGCCGA  
GluProAspLeuSerSerAspIleLysGluArgPheAlaGlnLeuCysGluLysHisGly  
421 GAACCAGATTTGAGTTCAGACATCAAGGAAAGGTTTGCACTATGTGAGAAGCATGGA  
IleLeuArgGluAsnIleIleAspLeuSerAsnAlaAsnArgCysLeuGlnAlaArgGlu  
481 ATCCTTAGAGAAAATATCATTGACCTATCCAATGCCAATCGCTGCCTCCAGGCCCGAGAA  
\*\*\*  
541 TGA

FIG. 7

GlyProLeuGlySerMetGluGlnLysLeuIleSerGluGluAspLeuThrMetGluAla  
1 GGGCCCCTGGGATCCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGACCATGGAAGCT  
SerSerThrGlyArgAsnPheAsnValGluLysIleAsnGlyGluTrpHisThrIleIle  
61 AGTTCTACGGGAAGGAACCTTTAATGTAGAAAAGATTAATGGGGAATGGCATACTATTATC  
LeuAlaSerAspLysArgGluLysIleGluAspAsnGlyAsnPheArgLeuPheLeuGlu  
121 CTGGCCTCTGACAAAAGAGAAAAGATAGAAGATAATGGCAACTTTAGACTTTTTCTGGAG  
GlnIleHisValLeuGluLysSerLeuValLeuLysPheHisThrValArgAspGluGlu  
181 CAAATCCATGTCTTGGAGAAATCCTTAGTTCTTAAATTCCATACTGTAAGAGATGAAGAG  
CysSerGluLeuSerMetValAlaAspLysThrGluLysAlaGlyGluTyrSerValThr  
241 TGCTCGGAATTATCTATGGTTGCTGACAAAACAGAAAAGGCTGGTGAATATTCTGTGACG  
TyrAspGlyPheAsnThrPheThrIleProLysThrAspTyrAspAsnPheLeuMetAla  
301 TATGATGGATTCAATACATTTACTATACCTAAGACAGACTATGATAACTTTCTTATGGCT  
HisLeuIleAsnGluLysAspGlyGluThrPheGlnLeuMetGlyLeuTyrGlyArgGlu  
361 CATCTCATTAAACGAAAAGGATGGGGAACCTTCCAGCTGATGGGGCTCTATGGCCGAGAA  
ProAspLeuSerSerAspIleLysGluGluArgPheAlaGlnLeuCysGluLysHisGlyIle  
421 CCAGATTTGAGTTCAGACATCAAGGAAAGGTTTGCACTATGTGAGAAGCATGGAATC  
LeuArgGluAsnIleIleAspLeuSerAsnAlaAsnArgCysLeuGlnAlaArgGlu\*\*\*  
481 CTTAGAGAAAATATCATTGACCTATCCAATGCCAATCGCTGCCTCCAGGCCCGAGAATGA

FIG. 8

6 / 15

1 GlyProLeuGlySerMetAlaIleIleValThrGlnThrMetLysGlyLeuAspIleGln  
 GGGCCCCTGGGATCCATGGCCATCATCGTCACCCAGACCATGAAAGGCCTGGACATCCAG  
 61 LysValAlaGlyThrTrpHisSerLeuAlaMetAlaAlaSerAspIleSerLeuLeuAsp  
 AAGGTGGCGGGGACTTGGCACTCCTTGGCTATGGCGGCCAGCGACATCTCCCTGCTGGAT  
 121 AlaGlnSerAlaProLeuArgValTyrValGluGluLeuLysProThrProGluGlyAsn  
 GCCCAGAGTGCCCCCTGAGAGTGACGTGGAGGAGCTGAAGCCCACCCCCGAGGGCAAC  
 LeuGluIleLeuLeuGlnLysTrpGluAsnGlyGluCysAlaGlnLysLysIleIleAla  
 181 CTGGAGATCCTGCTGCAGAAATGGGAGAACGGCGAGTGTGCTCAGAAGAAGATTATTGCA  
 GluLysThrLysIleProAlaValPheLysIleAspAlaLeuAsnGluAsnLysValLeu  
 241 GAAAAAACCAAGATCCCTGCGGTGTTCAAGATCGATGCCTTGAATGAGAACAAAGTCCTT  
 ValLeuAspThrAspTyrLysLysTyrLeuLeuPheCysMetGluAsnSerAlaGluPro  
 301 GTGCTGGACACCGACTACAAAAAGTACCTGCTCTTCTGCATGGAAAACAGTGCTGAGCCC  
 GluGlnSerLeuAlaCysGlnCysLeuValArgThrProGluValAspAsnGluAlaLeu  
 361 GAGCAAAGCCTGGCCTGCCAGTGCCTGGTCAGGACCCCGGAGGTGGACAACGAGGCCCTG  
 GluLysPheAspLysAlaLeuLysAlaLeuProMetHisIleArgLeuAlaPheAsnPro  
 421 GAGAAATTCGACAAAGCCCTCAAGGCCCTGCCATGCCATGCACATCCGGCTTGCCCTTCAACCCG  
 ThrGlnLeuGluGlyGlnCysHisValGluGlnLysLeuIleSerGluGluAspLeu\*\*\*  
 481 ACCCAGCTGGAGGGGCAGTGCCACGTCGAGCAGAACTCATCTCTGAAGAGGATCTGTAG

FIG. 9




FIG. 10

7 / 15




FIG. 11

8 / 15




FIG. 12




FIG. 13




FIG. 14

1

SmMUP

SM

SML

SML100

+++++  
 METDTLLLWVLLWVPGSTGDAQAQPARRARRTKLGTELGSMEQKLISEEDLTWEASTGRNFNVEKINGEWHHTIILASDKREKIEDNGNFRLFLEQIHVL  
 METDTLLLWVLLWVPGSTGDAQAQPAKMLLLCLGLTLVCVH-----AEEASTGRNFNVEKINGEWHHTIILASDKREKIEDNGNFRLFLEQIHVL  
 METDTLLLWVLLWVPGSTGDAQAQPAKMLLLCLGLTLVCVH-----AEEASTGRNFNVEKINGEWHHTIILASDKREKIEDNGNFRLFLEQIHVL  
 METDTLLLWVLLWVPGSTGDAQAQPAKMLLLCLGLTLVCVH-----AEEASTGRNFNVEKINGEWHHTIILASDKREKIEDNGNFRLFLEQIHVL

100

---

101

SmMUP

SM

SML

SML100

200  
 EKSLVLKFHTVRDECSSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYD-----NFTMAHLINЕКDGETFQLMGLYGREPDLSSDIKE  
 EKSLVLKFHTVRDECSSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYD-----NFTMAHLINЕКDGETFQLMGLYGREPDLSSDIKE  
 EKSLVLKFHTVRDECSSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYDKL---GTGSSS---EFNFTMAHLINЕКDGETFQLMGLYGREPDLSSDIKE  
 EKSLVLKFHTVRDECSSELSMVADKTEKAGEYSVTYDGFNTFTIPKTDYDKLVNRFSTIVRRRAEFNFTMAHLINЕКDGETFQLMGLYGREPDLSSDIKE

200

---

201

SmMUP

SM

SML

SML100

269  
 RFAQLCEKHGILRENIIDLNSANRCLQARE-----  
 RFAQLCEKHGILRENIIDLNSANRCLQAREEQKLISEEDLAAARGGPEQKLISEEDLNSAVDHHHHH-  
 RFAQLCEKHGILRENIIDLNSANRCLQAREEQKLISEEDLAAARGGPEQKLISEEDLNSAVDHHHHH-  
 RFAQLCEKHGILRENIIDLNSANRCLQAREEQKLISEEDLAAARGGPEQKLISEEDLNSAVDHHHHH-

269

FIG. 15



11 / 15




FIG. 16




FIG. 17

12 / 15

## FIG. 18

1	gtgctcagca	acacacccag	caccagcatt	cccgtgctc	ctgaggtctg	caggcagctc
61	gctgtagcct	gagcgggtgtg	gaggggaagt	tcctgggaga	tttaaaatgt	gagaggcggg
121	aggtgggagg	ttggggccctg	tgggcctgcc	catcccacgt	gcctgcatta	gccccagtgc
181	tgctcagccg	tgcccccgcc	gcaggggtca	ggtcactttc	ccgtccctggg	gttattatga
241	ctcttgtcat	tgccattgcc	atttttgcta	ccctaactgg	gcagcaggtg	cttgacagagc
301	cctcgatacc	gaccaggtcc	tccctcggag	ctcgacctga	accccatgtc	acccttgccc
361	cagcctgcag	agggtgggtg	actgcagaga	tcccttcacc	caaggccacg	gtcacatggt
421	ttggaggagc	tggtgcccac	ggcagaggcc	accctccagg	acacacctgt	ccccagtgc
481	ggctctgacc	tgctccttgc	taagaggctg	accccggag	tggtccctggc	actggcagcc
541	agcctggacc	cagagtccag	acacccacct	gtgccccgc	ttctgggggtc	taccaggaac
601	cgtctaggcc	cagaggggga	cttcctgctt	ggccttggat	ggaagaaggc	ctcctattgt
661	cctcgtagag	gaagccaccc	cggggcctga	ggatgagcca	agtgggattc	cgggaaccgc
721	gtggctgggg	gcccagcccc	ggctggctgg	cctgcctgctg	cctcctgtat	aaggcccaa
781	gcctgcctgt	ctcagccctc	cactccctgc	agagctcaga	agcacgacct	cagctgcagc
841	catgaagtgc	ctcctgcttg	ccctgggctt	ggccctcgcc	tggtggcgctc	aggccatcat
901	cgtcacccag	accatgaaag	gcctggacat	ccagaagggt	cgaggggttg	ccgggtgggt
961	gagttgcagg	gcgggcaggg	gagctggggc	tcagagagcc	aagagaggct	gtgacgttgg
1021	gttcccatca	gtcagctagg	gccacctgac	aaatccccgc	tggggcagct	tcaaccaggc
1081	gttcaactgtc	ttgcattctg	gaggctggaa	gcccagaatc	caggtgttgg	cagggctggc
1141	ttctcctgcg	gcccgtctct	ggggagcaga	cggccgtctt	ctccagtcct	ctgcgcgcc
1201	tgatttcctc	ttcctgtgag	gccaccaggc	ctgctggaaa	cacgcctgcc	tgcgagctt
1261	cacacgacct	ttgtcatctc	tttaaaggcc	atgtctccag	agtcattgtg	tgaagtctctg
1321	ggggttagtg	ggacacagtt	gaccccttaa	aagagtctct	ctgccccca	aattttcccc
1381	acctccagcc	atgtctcccc	aagatccaaa	tggtgctaca	tggtgggggg	ctcatctggg
1441	tccctctttg	ggttcagtgt	gagtcctggg	agagcattcc	ccaggtgca	gagttggggg
1501	gagtatctca	gggctgcccc	ggccgggggtg	ggacagagag	cccactgtgg	ggctgggggc
1561	cccttcccac	ccccagagtg	caactcaagg	tccctctcca	ggtggcgggg	acttggcact
1621	ccttggctat	ggcggccagc	gacatctccc	tgctggatgc	ccagagtgcc	cccctgagag
1681	tgtacgtgga	ggagctgaag	cccacccccg	agggcaacct	ggagatcctg	ctgcagaaat
1741	ggtgggcgtc	tctccccaac	atggaacccc	cactccccag	ggctgtggac	cccccgggg
1801	gtgggggtgca	ggagggacca	gggccccagg	gctggggaag	agggtcaga	gtttactggg
1861	accggcgct	ccacccaagg	ctgcccaccc	agggttttt	ttttttttaa	acttttatta
1921	atgtgatgtc	tcagaacatc	atcaaaacaa	tgaacataaa	acattcattt	ttgtttactt
1981	ggaaggggag	ataaaatcct	atgaagtgga	aatgcatagc	aaagatacat	acaatgaggg
2041	aggtattctg	aattccctgt	tagtctgagg	attacaagtg	tatttgagca	acagagagac
2101	attttcatca	tttctagtct	gaacacctca	gtatctaaaa	tgaacaagaa	gtcctggaaa
2161	cgaagcagtg	tggggatagg	cccgtgtgaa	ggctgctggg	aggcagcaga	cctgggtcct
2221	cgggctcaag	cagttcccg	taccagccct	gtccacctca	gacgggggtc	agggtgcagg
2281	agagagctgg	atgggtgtgg	ggcgagagat	ggggacctga	accccagggc	tgccttttgg
2341	gggtgcctgt	ggtaaggct	ctccctgacc	tttctctct	ggcttcatct	gacttctcct
2401	ggcccatcca	cccgggtccc	tggtggcctga	ggtgacagtg	agtgcgcgga	cttctagtgg
2461	ccagctggct	cctatgcccc	tgccaccccc	ctccagccct	cctgggccag	gttctgcccc
2521	tggccctcag	ttcatcctga	tgaaaatggt	ccatgccaat	ggctcagaaa	gcagctgtct
2581	ttcagggaga	acggcgagtg	tgctcagaag	aagattattg	cagaaaaaac	caagatccct
2641	gcggtgttca	agatcgatgg	tgagtccggg	tccctggggg	acacccacca	cccccgcccc
2701	cggggactgt	ggacagggtc	agggggctgg	cgtcggggcc	tgggatgcta	agggactggt
2761	ggtgatgaag	acactgcctt	gacacctgct	tcaattgcct	cccctgccac	ctgcccgggg
2821	ccttggggcg	gtggccatgg	gcaggtcccg	gctggcgggc	taaccacca	gggtgacacc
2881	cgagctctct	ttgctggggg	gcgggcgggtg	ctctggggcc	tcaggctgag	ctcaggaggt
2941	acctgtgccc	tcccaggggt	aaccgagagc	cgttgcccac	tccagggggc	caggtgcccc
3001	acgaccccag	cccgtccac	agctccttca	tctcctggag	acaaactctg	tccgcccctg
3061	ctcattcact	tggttcgtcct	aaatccgaga	tgataaagct	tcgagggggg	tttggggttc
3121	catcaggggt	gcccttccgc	cgggcagcct	gggccacatc	tgcccttggc	gctccaggga
3181	ctcactctga	ctggaggccc	tgactgact	gacgccaggg	tgcccagccc	agggtctctg
3241	gcgccatcca	gctgcactgg	gtttgggtgc	tggtcctgcc	cccaagctgc	cgggacacca
3301	caggcatccg	gggctgcccc	ctggcctcgg	tcaggggtgag	ccccagctgc	ccccgctcag
3361	ggcttgcccc	gacaatgacc	ccatcctcag	gacgcacccc	ccttcccttg	ctgggagtg
3421	tccagcccca	cccagagatcg	ggggaagccc	tatttcttga	caactccagt	cctggggga
3481	gggggcctca	gactgagtg	tgagtgttcc	caagtccagg	agggtggtgga	gggtcctggc
3541	ggatccagag	ttgacagtga	gggttccctg	ggcccatgc	gcctggcagt	ggcagcaggg
3601	aagaggaagc	accatttcag	gggtggggga	tgccagaggc	gctccccacc	ccgtcttcgc

13 / 15

```

3661 cgggtggtga ccccggggga gccccgctgg tcgtggaggg tgctgggggc tgactagcaa
3721 cccctcccc cccgttgaa ctcacttttc tcccgtcttg accgcgtcca gccttgaatg
3781 agaacaagt ccttgtgctg gacaccgact agccttgccct gccagtgccct cctgtcttct
3841 acagtgtgta gcccagcaaa ggggtgggtgc ggggtgggtgc ggggtgggtgc caacctggc
3901 tgcccaggga gaccagctgc gtggtccttg ctgcaacagg ctgagtcctcg ccaggagaga gtggtcgcat
3961 atccccagga ggaggagggg tgggggggtcc ctgagtcctcg acgggggcca gacacacagg
4021 accgggagcc agtctgctgt gggcctgtgg gtggctgggg cgtcgcgatg gggccggtgg
4081 ccgggagacg ggtgggctgc agaactgtga ctgggtgtgac tatttcccaa aataagaact
4141 tcaactgaatc taacagcctt aactatcaca tcctgaaaac aaatggcagg tgacattttc
4201 caggtacaaa gccatctttc gggcattttc agggcccctg tgccaggggg gcgcgggcat
4261 tgtgccgtag cagtccact aggtccttgg ctgtgtcagc cggcccaggg ggaggaaggg acccgagacg
4321 cggcgagtgg aggtccttgg tttccccctgt gacctgcaga cccactgcac tgccctggga
4381 ccagagggtg ggggcaggct caagggggaa gggcaggtgc tctggagggc aagggcagac
4441 ggaaggagg ggaactaggc cagggactga cccccgtccc tgccccatag tcaggacccc
4501 ctgcagacca ccctggggag tggagaaatt cgacaaaagcc ctcaaggccc ccccatgca
4561 ggaggtggac aacgaggccc cgaccagct ggaggtgag caccaggcc ccgcccctcc
4621 catccggctt gccttcaacc ccccgggagc acctcctccc atggtgacct ccagctcccc
4681 ccagggcagg agccaccgg gtggggtgca gacccccgtg ggggccccct cccaccccc
4741 aggcctccca ggaggaagg ggtgtccag cccatcctga ccccccatg actctccctc
4801 tgccaggcct ctctcccga tctagtgag cccctgcccg tgccctggg gtaagctgac
4861 cccacaggg cagtccacg gcacacacat ggggtagggg gtcttgggtg ggcctgggac
4921 tgccctgccc cacgtcctgg cccccctgtg agaatggctg gaagctgggg tccctcctgg
4981 cccacatcag gcccgtgggt cgcgtgccac tcttgtgggt gacctgtgtc ctggcctcac
5041 cgactgcaga gctggctggc cttccagcag agctaaggct aagttagcca gaatggtacc
5101 acactgacct cctccagctc ttatcccgag gaggggctgt cctggaacca ccagccatgg
5161 taaggggagg ctagcggctc caggtgcccc aggaatcaca ggggggcccc atgtccattt
5221 agaggctggc aagggtctgg ctccctctgg gacagacgac gtcaccaccg ccccccccc
5281 cagggcccgg gagccttggg ccaggactgc agtcaccctt cctgggacct cctgggacct
5341 atcaggggga ctagaaggga gctctgggca gcttctcctt caccaataaa ggcataaacc
5401 agggccctcc tggggctcct tttgtctggc gacgggcagg ggggtggagaa gtggtgggga
5461 tgtgctctcc cttctgagtc gacagcgggg ggggatcca gggcgctcgc atcacagtct
5521 gggagtctgg ctacagagat gggggccac acacatcact ggggctcttt gaaactttca gaaaccaggg
5581 tgtgacaact gggggccac cagagacatc tgccagttca cttggagtgt tcagtcaaca cccaaactcg
5641 agggactcgg gaaagtggaa aatggctgtc tcttagtcta ataatattg atatgaaact
5701 acaaaggaca atggatcaat atgcctttat gatccagcca gccactactg tcgtatcaac
5761 caagtgtctc aaacgcactg actgtctgga ctaatgatga gagattccca gtatccagg
5821 tcatgtatcc cactgtgaga actgtctgca cacacagcag agtccaccag tcatctaaag
5881 ggcaagaggt ctggtgttca ttggaggact gatgttgaag ctgaaactcc aatgctttgg
5941 gagatcagtc tgaagagctg actcatttga aaagaccctg atgctgggaa agattgaggg
6001 ccacctgatg aggggacgac agaggatgag atggttggat ggcacacca acacaatgga
6061 caggaggaga ggtggactcc agaggttggg gatggacagg gaggcctggc gtgctacgga
6121 catgggtttg ggggtcacaa actgaactga gctgaactga gctgaactga atggaaatga
6181 agcggtttat aaagtgggga ttttttagat tacacataac atagtgtata
6241 ggtatacagc tatgcatacc tgaatgtctc gtcactcagt cgtatctgac tctgtgacct
6301 ctcatatttt gccttccagg tttcttctgt ccacagaatt ctccaaggca agaatactgg
6361 atggaccgta ctttccctcc tccaggggat cctcccgacc cagggattga accggcatct
6421 agtgggtagc caggtggatt ctttaccact gggccaccag ggaagcccg gttactctct
6481 cctgtattgg taattaccaa agctgctcca agaaaaagcc cctgtgccct ctgagcttcc
6541 atgtccact aggggtgggg gggtagactg tgacctggga acacctccc gcttcaggac
6601 cggcctgcag aggtggtgg agtcctgcag acagccgggt agctctgctc ttcaaggctc
6661 tcccgggcca cgtgaccac aggtctattt tctctcccag cctcaggggg ttctgaacat
6721 attatcttta aaaaaaactg tctctcccag gggtgctcac cttcaggggg ccagccttca
6781 ccagtgcgat ggcagggacc cgggggtggc ggggtgctca aggtctccca agtcttccca
6841 cctatgagtc accagacact gaccaatgac caagcagaca cccacaggac
6901 tcgtcctgat caaagagcaa agctgtcctt agacacacag ctctcgaagg
6961 actgaggttc accagagctg taaggcctac agaggggaaga cagtccctgca
7021 ttttctcttt aatctggatt ggtggcatcc gaggccactt gaccgacccc ccagaggcct
7081 tgtcccagg acagccactc tggacaacaa ccttgggtgg tatgttatg gacgtatata
7141 tggaaattaat cggtccaaac ccttgggtgg ttttttcttt tggtgtgct ggctgttcgt
7201 caaccatcct gctttgacca tttcattttt tggctgtgct gcctgttcgt
7261 tatatatata tttttttttt tttctcttag tcacagagca gtctctaga
7321 tgcgcaggct tctctctagt

```

FIG. 18 CONT'D

14 / 15

MKCLLLALGLALACGVQAIIVTQTMKGLDIQKVAGTWHSLAMAA  
SDISLLDAQSAPLRVYVEELKPTPEGNLEILLQKWENGECAQKKIIAEKTKIPAVFKI  
DALNENKVLVLDTDYKKYLLFCMENSAPPEQSLACQCLVRTPEVDNEALEKFDKALKA  
LPMHIRLAFNPTQLEGQCHV

## FIG. 19

1	ctgaacccag	agagtatata	agaacaagca	aaggggctgg	ggagtggagt	gtagccacga
61	tcacaagaaa	gacgtggtcc	tgacagacag	acaatcctat	tccctaccaa	aatgaagatg
121	ctgctgctgc	tgtgtttggg	actgacccta	gtctgtgtcc	atgcagaaga	agctagttct
181	acgggaagga	actttaatgt	agaaaagatt	aatggggaat	ggcatactat	tatcctggcc
241	tctgacaaaa	gagaaaagat	agaagataat	ggcaacttta	gactttttct	ggagcaaatc
301	catgtcttgg	agaattcctt	agttcttaaa	ttccatactg	taagagatga	agagtgtctg
361	gaattatcta	tggttgctga	caaaacagaa	aaggctgggtg	aataattctgt	gacgtatgat
421	ggattcaata	catttactat	acctaagaca	gactatgata	acttttcttat	ggctcatctc
481	attaacgaaa	aggatgggga	aaccttccag	ctgatggggc	tctatggccg	agaaccagat
541	ttgagttcag	acatcaagga	aaggtttgca	caactatgtg	agaagcatgg	aatccttaga
601	gaaaatatca	ttgacctatc	caatgccaat	cgctgcctcc	aggcccagga	atgaagaatg
661	gcctgagcct	ccagtgttga	gtggagactt	ctcaccagga	ctccaccatc	atcccttcct
721	atccatacag	catccccagt	ataaattctg	tgatctgcat	tccatcctgt	ctcactgaga
781	agtccaattc	cagtctatcc	acatgtttacc	taggatacct	catcaagaat	caaagacttc
841	tttaaatatt	tctttgatat	acccatgaca	atttttcatg	aatttcttcc	tcttcctggt
901	caataaatga	ttacccttgc	actta			

## FIG. 20

MKMLLLLCGLTLVCVHAEESSTGRNFNVEKINGEWHTIILAS  
DKREKIEDNGNFRFLFLEQIHVLENSLVLFHTVRDEECSELSMVADKTEKAGEYSVTY  
DGFNTFTIPKTDYDNFLMAHLINEKDGETFQLMGLYGREPDLSSDIKERFAQLCEKHG  
ILRENIIDLNSNANRCLQARE

## FIG. 21

1	ctgctgctgc	tgtgtctgcg	cctgacactg	gtctgtggcc	atgcagaaga	agctagttcc
61	acaagagggg	acctcgatgt	ggctaagctc	aatggggatt	ggttttctat	tgtcgtggcc
121	tctaacaaaa	gagaaaagat	agaagagaat	ggcagcatga	gagtttttat	gcagcacatc
181	gatgtcttgg	agaattcctt	aggcttcaag	ttccgtatta	aggaaaatgg	agagtgcagg
241	gaactatact	tggtttccta	caaaacgcca	gaggatgggtg	aataattttgt	tgagtatgac
301	ggagggaata	catttactat	acttaagaca	gactactaca	tatacgtcat	gtttcatctc
361	attaatttca	agaacgggga	aaccttccag	ctgatgggtg	tctacggcag	aacaaaggat
421	ctgagttcag	acatcaagga	aaagtttgca	aaactatgtg	aggcgcatgg	aatcactagg
481	gacaatatca	ttgatctaac	caagactgat	cgctgtctcc	aggcccaggg	atgaagaaag
541	gcctgagcct	ccagtgtctga	gtggagactt	ctcaccagga	ctctagcatc	accatttcct
601	gtccatggag	catcctgaga	caaattctgc	gatctgattt	ccatcctctg	tcacagaaaa
661	gtgcaatcct	ggtctctcca	gcattctccc	tagttaccca	ggacaacaca	tcgagaatta
721	aaagctttct	taaatcttct	ttggccccac	ccatgatcat	tccgcacaaa	tatcttgctc
781	ttgcagttca	ataaatgatt	acccttgca	ttt		

## FIG. 22

15 / 15

atgtccctatactaggttattggaaaattaagggccttgtgcAaccactcgacttcttttgaatatcttgaagaaaaatatga  
 agagcattttagtgagcgcgatgaagggtataaatggcgaaacAaaaagtttgaattgggttggagtttcccaatcttcctta  
 ttatattgatggtgatgttaaattaacacagtctatggccatcatacttatatagctgacaagcacacaatgttgggtggtgtc  
 caaaagagcgtgcagagattcaatgcttgaaggagcgggtttggatattagatacgggtgttcgagaattgcataatagtaaa  
 gactttgaactctcaaaagttgattttcttagcaagctacgtgaaatgctgaaatgttcgaagatcggttatgtcataaaacatat  
 ttaaattggtgatcatgaaccatcctgacitcatgtttagacgctcttgatgttgtttatacatggaccaatgtgcctggat  
 gcgttcccaaaattagttgttttaaaaaacgtattgaagctatcccaaaatgataagtacttgaatccagcaagtatatagc  
 atggcctttgcagggctggcaagccacgtttgggtggcgaccatcctccaaaatcggaatctggaagttctgtccagggg  
 cccctgggatccccggaattccgggtcgactcgagcggccgcacgtgactga

241														
281	Lys	Ile	Lys	Gly	Leu	Val	Gln	Pro	Thr	Arg	Leu	Leu	Leu	
	AAA	ATT	AAG	GGC	CTT	GTG	CAA	CCC	ACT	CGA	CTT	CTT	TTG	
321	Glu	Tyr	Leu	Glu	Glu	Lys	Tyr	Glu	Glu	His	Leu	Tyr	Glu	Arg
	GAA	TAT	CTT	GAA	GAA	AAA	TAT	GAA	GAG	CAT	TTG	TAT	GAG	CGC
361	Asp	Glu	Gly	Asp	Lys	Trp	Arg	Asn	Lys	Lys	Phe	Glu	Leu	
	GAT	GAA	GGT	GAT	AAA	TGG	CGA	AAC	AAA	AAG	TTT	GAA	TTG	
401	Gly	Leu	Glu	Phe	Pro	Asn	Leu	Pro	Tyr	Tyr	Ile	Asp	Gly	
	GGT	TTG	GAG	TTT	CCC	AAT	CTT	CCT	TAT	TAT	ATT	GAT	GGT	
441	Asp	Val	Lys	Leu	Thr	Gln	Ser	Met	Ala	Ile	Ile	Arg	Tyr	Ile
	GAT	GTT	AAA	TTA	ACA	CAG	TCT	ATG	GCC	ATC	ATA	CGT	TAT	ATA
481	Ala	Asp	Lys	His	Asn	Met	Leu	Gly	Gly	Cys	Pro	Lys	Glu	
	GCT	GAC	AAG	CAC	AAC	ATG	TTG	GGT	GGT	TGT	CCA	AAA	GAG	
521	Arg	Ala	Glu	Ile	Ser	Met	Leu	Glu	Gly	Ala	Val	Leu	Asp	
	CGT	GCA	GAG	ATT	TCA	ATG	CTT	GAA	GGA	GCG	GTT	TTG	GAT	
561	Ile	Arg	Tyr	Gly	Val	Ser	Arg	Ile	Ala	Tyr	Ser	Lys	Asp	Phe
	ATT	AGA	TAC	GGT	GTT	TCG	AGA	ATT	GCA	TAT	AGT	AAA	GAC	TTT
601	Glu	Thr	Leu	Lys	Val	Asp	Phe	Leu	Ser	Lys	Leu	Pro	Glu	
	GAA	ACT	CTC	AAA	GTT	GAT	TTT	CTT	AGC	AAG	CTA	CCT	GAA	
641	Met	Leu	Lys	Met	Phe	Glu	Asp	Arg	Leu	Cys	His	Lys	Thr	
	ATG	CTG	AAA	ATG	TTC	GAA	GAT	CGT	TTA	TGT	CAT	AAA	ACA	
681	Tyr	Leu	Asn	Gly	Asp	His	Val	Thr	His	Pro	Asp	Phe	Met	Leu
	TAT	TTA	AAT	GGT	GAT	CAT	GTA	ACC	CAT	CCT	GAC	TTC	ATG	TTG
721	Tyr	Asp	Ala	Leu	Asp	Val	Val	Leu	Tyr	Met	Asp	Pro	Met	
	TAT	GAC	GCT	CTT	GAT	GTT	GTT	TTA	TAC	ATG	GAC	CCA	ATG	
761	Cys	Leu	Asp	Ala	Phe	Pro	Lys	Leu	Val	Cys	Phe	Lys	Lys	
	TGC	CTG	GAT	GCG	TTC	CCA	AAA	TTA	GTT	TGT	TTT	AAA	AAA	
801	Arg	Ile	Glu	Ala	Ile	Pro	Gln	Ile	Asp	Lys	Tyr	Leu	Lys	Ser
	CGT	ATT	GAA	GCT	ATC	CCA	CAA	ATT	GAT	AAG	TAC	TTG	AAA	TCC
841	Ser	Lys	Tyr	Ile	Ala	Trp	Pro	Leu	Gln	Gly	Trp	Gln	Ala	
	AGC	AAG	TAT	ATA	GCA	TGG	CCT	TTG	CAG	GGC	TGG	CAA	GCC	
881	Thr	Phe	Gly	Gly	Gly	Asp	His	Pro	Pro	Lys	Ser	Asp	Leu	
	ACG	TTT	GGT	GGT	GGC	GAC	CAT	CCT	CCA	AAA	TCG	GAT	CTG	
921	Glu	Val	Leu	Phe	Gln	Gly	Pro	Leu						
	GAA	GTT	CTG	TTC	CAG	GGG	CCC	CTG						

FIG. 23

(19) World Intellectual Property  
Organization  
International Bureau



26 JAN 2005



(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
**WO 2004/011676 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/62,  
C07K 14/47, C12Q 1/68, G01N 33/68

(21) International Application Number:  
PCT/GB2003/003192

(22) International Filing Date: 25 July 2003 (25.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0217402.7 26 July 2002 (26.07.2002) GB

(71) Applicants (for all designated States except US): ROSLIN  
INSTITUTE (EDINBURGH) [GB/GB]; Roslin, Midlothian  
EH25 9PS (GB). CXR BIOSCIENCES LIMITED  
[GB/GB]; Dundee Technopole, James Lindsay Place,  
Dundee DD1 5JJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WHITELAW,  
Christopher, Bruce, Alexander [GB/GB]; Roslin Insti-  
tute (Edinburgh), Roslin, Midlothian EH25 9PS (GB).

CLARK, Anthony, John [GB/GB]; Roslin Institute  
(Edinburgh), Roslin, Midlothian EH25 9PS (GB). WOLF,  
Charles, Roland [GB/GB]; CXR Biosciences Limited,  
James Lindsay Place, Dundee Technopole, Dundee DD1  
5JJ (GB).


(74) Agents: BASSIL, Nicholas, Charles et al.; Kilburn &  
Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: MULTI-REPORTER GENE MODEL FOR TOXICOLOGICAL SCREENING



(57) Abstract: A system for the detection of gene activation events is provided which comprises a nucleic acid construct encoding a protein of the lipocalin protein family and a peptide tag in which the expression of the construct in a cell or in the cells of a transgenic animal demonstrates the activation of a gene or genes of interest, in which the protein expressed is secreted from the cell and in which detection of the peptide tag indicates expression of the construct.

WO 2004/011676 A3

**Declarations under Rule 4.17:**

- as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO

patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

6 May 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/03/03192

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/62 C07K14/47 C12Q1/68 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N C12Q A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MCCLLENAGHAN M ET AL: "Insertion of a casein kinase recognition sequence induces phosphorylation of ovine beta-lactoglobulin in transgenic mice" PROTEIN ENGINEERING, vol. 12, no. 3, March 1999 (1999-03), pages 259-264, XP002259482 ISSN: 0269-2139 cited in the application	1,2,9-12
Y	the whole document	3,4
X	WO 02/053701 A (LAREYRE JEAN-JACQUES ; UNIV VANDERBILT (US); MATUSIK ROBERT J (US); OR) 11 July 2002 (2002-07-11)	1
Y	figure 7; example 12	3,4
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\* & \* document member of the same patent family

Date of the actual completion of the international search

16 February 2004

Date of mailing of the international search report

01 03. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/ 3/03192

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHLEHUBER STEFFEN ET AL: "A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 297, no. 5, 14 April 2000 (2000-04-14), pages 1105-1120, XP002150338 ISSN: 0022-2836	1,3,5,9
Y	page 1112, column 1, paragraph 2 - page 1115, column 2, paragraph 4; figures 2,10,11	3,4
X	WO 00/75308 A (SKERRA ARNE ; SCHLEHUBER STEFFEN (DE)) 14 December 2000 (2000-12-14)	1,2,5
Y	the whole document	3,4
X	SUI DEXIN; WILSON JOHN E: "Interaction of insulin-like growth factor binding protein-4, Miz-1, leptin, lipocalin-typ prostaglandin D synthase, and granulin precursor with the N-terminal half of Type III -hexokinase" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 382, no. 2, 15 October 2000 (2000-10-15), pages 262-274, XP0001172430 the whole document	1
X	SUNDARAM M ET AL: "Expression, characterization and engineered specificity of rat epididymal retinoic-acid binding protein" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 334, no. 1, 15 August 1998 (1998-08-15), pages 155-160, XP002095127 ISSN: 0264-6021 page 156, column 1, paragraph 2 - column 2, paragraph 2; figure 1	1

-/--

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/03/03192

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHMIDT A M ET AL: "A ZN(II)-BINDING SITE ENGINEERED INTO RETINOL-BINDING PROTEIN EXHIBITS METAL-ION SPECIFICITY AND ALLOWS HIGHLY EFFICIENT AFFINITY PURIFICATION WITH A NEWLY DESIGNED METAL LIGAND" CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 3, no. 8, August 1996 (1996-08), pages 645-653, XP001117565 ISSN: 1074-5521 page 647, column 2, paragraph 3 - page 648, column 1, paragraph 3	1
X	US 6 114 123 A (BAUGHN MARIAH R ET AL) 5 September 2000 (2000-09-05) the whole document	1,9-12
X	CROSSETT, B. ET AL.: "Transfer of a uterine lipocalin from the endometrium of the mare to the developing equine conceptus" BIOLOGY OF REPRODUCTION, vol. 59, 1998, pages 483-490, XP002259483 the whole document	1
A	WO 97/07132 A (COMMW SCIENT IND RES ORG ; WANG LINFA (AU)) 27 February 1997 (1997-02-27) the whole document	1,3,4,9
Y		3,4
Y	US 5 948 677 A (JARVIK JONATHAN W) 7 September 1999 (1999-09-07) the whole document	3,4
A	WO 98/30715 A (ISACOFF EHUD Y ; SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFORNIA) 16 July 1998 (1998-07-16) the whole document	1,9-21
Y		15-18
A	WO 02/01949 A (UNI DEGLI STUDI DI MILANO ; CIANA PAOLO (IT); MAGGI ADRIANA CATERINA ) 10 January 2002 (2002-01-10) the whole document	1,9-21
A	WO 99/37142 A (JORGENSEN TRINE NOERGAARD ; MICHELSEN BIRGITTE KOCH (DK); NOVONORDISK) 29 July 1999 (1999-07-29) the whole document	9-21
A	EP 1 130 086 A (DEUTSCHES KREBSFORSCH ; TPSC TECHNOLOGIES DU PROMOTEUR (FR)) 5 September 2001 (2001-09-05) the whole document	19
	-/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/03/03192

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 111 387 A (JAPAN SCIENCE & TECH CORP ; OSAKA BIOSCIENCE INST (JP); MARUHA CORP (J) 27 June 2001 (2001-06-27) the whole document	21
X	----- WO 02/31151 A (BRUNS CHRISTOPHER M ; HAFALIA APRIL J A (US); INCYTE GENOMICS INC (US)) 18 April 2002 (2002-04-18)	1,3, 15-18
Y	page 1, line 27 - page 2, line 27 page 33, line 35 - page 34, line 12 page 41, line 12 - line 24 page 44, line 33 - page 45, line 30 page 51, line 29 - page 52, line 34 page 68, line 35 - page 69, line 11; claims 7,8,20,23,27-29 -----	15-18

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 03/03192

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
As far as claims 13 to 21 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
1-6 9-21
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6, 9-21 (all partially)

A nucleic acid construct comprising (i) a nucleic acid sequence encoding a member of the lipocalin protein family, and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues; said nucleic acid construct when the lipocalin is ovine betalactoglobulin (BLG) (accession No X12817); a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said ovine betalactoglobulin is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged ovine BLG reporter gene;

---

2. claims: 1-6, 9-21 (all partially)

A nucleic acid construct comprising (i) a nucleic acid sequence encoding murine major urine protein (MUP) (accession No NM 031188) and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues; a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said murine MUP is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged murine MUP reporter gene;

---

3. claims: 1-6, 9-21 (all partially)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A nucleic acid construct comprising (i) a nucleic acid sequence encoding rat alpha-2-urinary globulin (alpha -2u) (accession number M27434) and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues; a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said rat alpha-2-urinary globulin (alpha -2u) is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged rat alpha-2-urinary globulin (alpha -2u) reporter gene;

---

## 4. claims: 7- 8 and partially 9-21

A nucleic acid construct comprising a stress inducible promoter operatively isolated from a nucleic acid sequence encoding a member of the lipocalin protein family by a nucleic acid sequence flanked by nucleic acid sequence s recognised by a site specific recombinase, or by insertion such that it is inverted with respect to the transcription unit encoding a member of the lipocalin protein family, in which the construct additionally comprises a nucleic acid sequence comprising a tissue specific promoter operatively linked to a gene encoding the coding sequence for the site specific recombinase; a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said lipocalin is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene

---

## 5. claims: 15-16, 18 (all partially)

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

The use of a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, for the detection of a gene activation event resulting from a change in altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene, as far as not covered by a previous subject;

---

**6. claim: 18 (partially)**

A method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene, as far as not covered by a previous subject;

---

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB/03192

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02053701	A	11-07-2002	WO 02053701 A2	11-07-2002
WO 0075308	A	14-12-2000	DE 19926068 C1	11-01-2001
			AU 5963900 A	28-12-2000
			CA 2376638 A1	14-12-2000
			WO 0075308 A1	14-12-2000
			EP 1181368 A1	27-02-2002
US 6114123	A	05-09-2000	AU 4711400 A	02-01-2001
			CA 2375386 A1	21-12-2000
			EP 1185640 A1	13-03-2002
			JP 2003502041 T	21-01-2003
			WO 0077203 A1	21-12-2000
WO 9707132	A	27-02-1997	AU 700977 B2	14-01-1999
			AU 6696496 A	12-03-1997
			WO 9707132 A1	27-02-1997
			CA 2229540 A1	27-02-1997
			EP 0845004 A1	03-06-1998
			JP 11510683 T	21-09-1999
US 5948677	A	07-09-1999	AU 721832 B2	13-07-2000
			AU 5691998 A	03-07-1998
			EP 0961838 A1	08-12-1999
			WO 9826094 A1	18-06-1998
			US 6265545 B1	24-07-2001
WO 9830715	A	16-07-1998	AU 5090498 A	03-08-1998
			WO 9830715 A1	16-07-1998
			US 6660844 B1	09-12-2003
WO 0201949	A	10-01-2002	IT MI20001503 A1	04-01-2002
			AU 8194601 A	14-01-2002
			WO 0201949 A2	10-01-2002
			EP 1298988 A2	09-04-2003
			US 2003182676 A1	25-09-2003
WO 9937142	A	29-07-1999	AU 2512299 A	09-08-1999
			WO 9937142 A1	29-07-1999
EP 1130086	A	05-09-2001	EP 1130086 A1	05-09-2001
			CA 2400706 A1	23-08-2001
			WO 0160982 A1	23-08-2001
			JP 2003523201 T	05-08-2003
			US 2003175959 A1	18-09-2003
EP 1111387	A	27-06-2001	JP 2000146980 A	26-05-2000
			AU 750574 B2	25-07-2002
			AU 5449199 A	27-03-2000
			CA 2342897 A1	16-03-2000
			EP 1111387 A1	27-06-2001
			WO 0014543 A1	16-03-2000
WO 0231151	A	18-04-2002	AU 9683101 A	22-04-2002
			CA 2425767 A1	18-04-2002
			EP 1325128 A2	09-07-2003
			WO 0231151 A2	18-04-2002